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9 CONCLUSION 
In the present study attempts were made to formulate 150mg immediate release oral 
disintegrating tablet formulation which can provide effective and fast drug release in oral cavity. 
 EMRB042 oral disintegrating tablets were prepared by direct compression method. In vitro 
study showed formulation F10 & F11 were well suited for O.D.T formulation. 
From the results obtained, it can be concluded that formulation F10 & F11 has achieved the 
objective of faster drug release, patient convenience and cost effectiveness as direct compression 
technology is used against the lyophilization technology used by innovator.   
1) The use of sodium Stearyl Fumarate instead of magnesium stearate provided better release 
pattern. 
2) Ludiflash due to polyvinyl acetate content increased disintegration time & therefore alters the 
release of the A.P.I.  
3) Peroxide content of the Crospovidone played an important role in controlling the impurity in 
the formulation. 
4) Use of calcium silicate as co-disintegrant provided better D.T & dissolution. 
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1 INTRODUCTION 
1.1 Orally disintegrating dosage forms 
Orally disintegrating tablets (ODTs) are distinguished from conventional, sublingual tablets, 
buccal tablets and lozenges, which require more than a minute to dissolve in oral cavity. In the 
literature, ODTs also are called orodispersible, mouth dissolving, quick dissolve, fast melt and 
freeze dried wafers. 
A quick dissolving tablet (also known as a fast dissolving, fast dissolving multi particulate, rapid 
dissolving, mouth dissolving, fast melting, or orodispersible tablets) is an oral tablet that does not 
require water for swallowing. The tablet dissolves within 60 seconds when placed in the mouth. 
The active ingredients are absorbed through mucous membranes in the mouth and 
gastrointestinal tract (GIT) and enter the blood stream. A fraction of pregastric drug absorption 
may bypass the digestive system and metabolism by the stomach acids and enzymes. In general, 
the tablets are physically robust and can be packaged in multi dose containers  
A freeze dried wafer is a quick dissolving, thin matrix that contains a medicinal agent that does 
not need water for swallowing. This fragile dosage form requires unit dose packaging to ensure 
physical stability. The wafer disintegrates instantaneously in the oral cavity and releases drug, 
which dissolves in the saliva. The saliva is swallowed and the drug is absorbed across the 
GIT.Fast disintegrating or orodispersible tablets (ODTs) are one such novel approach to increase 
consumer acceptance by virtue of rapid disintegration, self administration without water or 
chewing. This delivery system offers convenience for treatment resistant population who has 
difficulty in swallowing unit oral dosage form, namely tablets and capsules. The demand for 
these formulations is particularly beneficial to pediatric and geriatric patients. It is estimated that 
50 % of the population is affected by dysphagia which results in high incidence of 
noncompliance and ineffective therapy. To overcome this problem, it is necessary to design a 
formulation which rapidly disperse / dissolve in the oral cavity without the need of water for 
swallowing. Such dosage form should disintegrate when placed in the mouth and can be 
swallowed in the liquid form. 
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The major advantage of mouth dissolving tablets is high patient compliance and its disintegration 
in mouth; this could enhance the clinical effect of drug through pregastric absorption from 
mouth, pharynx and esophagus. In such a case bioavailability of a drug is significantly greater 
than those observed from conventional tablet dosage form by avoiding first pass metabolism. 
Moreover, they overcome the swallowing difficulty associated with geriatric, pediatric or 
psychiatric patients and for the conditions where patients may not have ready access to water 
thus, it provides convenience of administration, greater patient compliance and quick onset of 
action. 
Due to the constraints of the current fast dissolving tablet (FDTs) technologies as highlighted 
above, there is an unmet need for improved manufacturing processes for FDTs that are 
mechanically strong, allowing ease of handling and packaging and with production costs similar 
to that of conventional tablets1 
1.2 Need to formulate orodispersible tablets1  
The need for non invasive drug delivery systems continues due to patient’s poor acceptance and 
compliance with existing delivery regimes, limited market size for drug companies and drug uses 
coupled with high cost of disease management. Developing new drug delivery technologies and 
utilizing them in product development is critical for pharmaceutical companies. Pharmaceutical 
marketing is another reason for development of new dosage form because it allows a 
manufacturer to extend market exclusivity, while offering its patients population with a more 
improved and convenient dosage form. 
The majority of patients receiving such preparations have little understanding of this new dosage 
form. Patients may be surprised when tablets begin to dissolve in the mouth. They might expect a 
faster onset of therapeutic action. Clarification from the pharmacist can avoid any confusion or 
misunderstanding1. 
1.3 Advantages of orodispersible tablets2 
1. Improved patient compliance.  
2. Rapid onset of action and may offer an improved bioavailability.  
3. Patient having difficulty in swallowing tablet can easily administer this type of dosage 
form. 
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4. Useful for pediatric, geriatric and psychiatric patients.  
5. Suitable during traveling where water is may not be available. 
6. Gives accurate dosing as compared to liquids.  
7. Good chemical stability. 
8. Pregastric absorption of drugs avoids hepatic metabolism, which reduces the dose and 
increase the bioavailability. 
9. An increased bioavailability, particularly in cases of insoluble and hydrophobic drugs, 
due to rapid disintegration and dissolution of these tablets 
1.4 Limitations 
1. In case of bitter drugs the taste have to be masked by various techniques which in turn 
increases the time and cost of production. 
2. Drugs to be absorbed at a particular site cannot be given in this dosage form. 
3. Tablets are very fragile and lack physical resistance. Because the tablets are very porous 
and low compression forces are used to prepare them. Therefore they cannot be packed in 
conventional strips or in bottles. Special packaging is required. 
1.5 Orodispersible tablets should have following properties2 
1. They should disintegrate with the help of saliva within a matter of seconds. 
2. They should be compatible with taste masking agent. 
3. They should be portable without fragility concerns. 
4. They should have a pleasing mouth feel. 
5. They should leave minimal or no residue in mouth after oral administration. 
6. They should exhibit low sensitivity to environment at conditions such as humidity and 
temperature. 
7. They should allow manufacturer to use conventional processing and packaging 
equipments at low cost. 
8. be adaptable and amenable to existing processing and packaging machinery 
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1.6 Mechanism for rapid disintegration3 
 To ensure that the tablet is fast dissolving, water must quickly egress into the tablet matrix to 
cause rapid disintegration and instantaneous dissolution of the tablet. Maximizing the porous 
structure of the tablet matrix and incorporating an appropriate disintegrating agents or highly 
water soluble excipients in the tablet formulation are the basic approaches used in current fast 
dissolving tablet technologies. Basically, the disintegrant’s major function is to oppose the 
efficacy of the tablet binder and the physical forces that act under compression to form the tablet. 
The mechanism by which tablet is broken down into smaller particles and then produces a 
homogeneous suspension or solution is based on following mechanisms 
1. Capillary action 
2. High swellability of disintegrants  
3. Capillary action and high swellability 
4. Because of heat of wetting (Air expansion)  
5. Due to particle repulsive forces 
6. Due to deformation 
7. Chemical reaction (Release of gases)  
8. By enzymatic reaction 
1.6.1 Capillary action 
Disintegration by capillary action is always the first step. When we put the tablet into suitable 
aqueous medium, the medium penetrates into the tablet and replaces the air adsorbed on the 
particles, which weakens the intermolecular bond and breaks the tablet into fine particles. Water 
uptake by tablet depends upon hydrophilicity of the drug /excipients and on tabletting conditions. 
For these types of disintegrants, maintenance of porous structure and low interfacial tension 
towards aqueous fluid is necessary which helps in disintegration by creating a hydrophilic 
network around the drug particles. 
1.6.2 High Swellability 
Perhaps the most widely accepted general mechanism of action for tablet disintegration is 
swelling tablets with high porosity show poor disintegration due to lack of adequate swelling 
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force. On the other hand, sufficient swelling force is exerted in the tablet with low porosity. It is 
worthwhile to note that if the packing fraction is very high, fluid is unable to penetrate in the 
tablet and disintegration is again slows down. 
 
                         Figure No.1.1: Disintegration of tablet by wicking and swelling action. 
1.6.3 Heat of wetting (Air expansion) 
When disintegrants with exothermic properties gets wetted, localized stress is generated due to 
capillary air expansion, which helps in disintegration of tablet. This explanation, however, is 
limited to only a few types of disintegrants and cannot describe the action of most modern 
disintegrating agents. 
1.6.4 particle repulsive forces 
Another mechanism of disintegration attempts to explain the swelling of tablet made with ‘non-
swellable’ disintegrants. The non swelling particle also causes disintegration of tablets. The 
electric repulsive forces between particles are the mechanism of disintegration and water is 
required for it. Researchers found that repulsion is secondary to wicking. 
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1.6.5 Deformation 
During tablet compression, disintegrated particles get deformed and these deformed particles get 
into their normal structure when they come in contact with aqueous media or water. 
Occasionally, the swelling capacity of starch was improved when granules were extensively 
deformed during compression. This increase in size of the deformed particles produces a breakup 
of the tablet. This may be a mechanism of starch and has only recently begun to be studied. 
 
                             Figure No.1.2. Disintegration by Deformation and Repulsion. 
1.6.6 Chemical reaction (Release of Gases)   
Carbon dioxide released within tablets on wetting due to interaction between bicarbonate and 
carbonate with citric acid or tartaric acid. The tablet disintegrates due to generation of pressure 
within the tablet. This effervescent mixture is used when pharmacist needs to formulate very 
rapidly dissolving tablets or fast disintegrating tablet. As these disintegrants are highly sensitive 
to small changes in humidity level and temperature, strict control of environment is required 
during manufacturing of the tablets. The effervescent blend is either added immediately prior to 
compression or can be added in to two separate fraction of formulation. 
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 1.6.7 Enzymatic reaction 
Enzymes presents in the body also act as disintegrants. These enzymes destroy the binding action 
of binder and helps in disintegration. Actually due to swelling, pressure exerted in the outer 
direction or radial direction, it causes tablet to burst or the accelerated absorption of water 
leading to an enormous increase in the volume of granules to promote disintegration. 
1.7 Ingredients used for orodispersible tablets 
1. They should allow quick release of the drug, resulting in faster dissolution and includes 
both the actives and the excipients.  
2. The binder should maintain the integrity and stability of the tablet during compression. 
3. The temperature of the excipient should be preferably around 30–35°C for faster melting 
properties.  
4. The incorporation of binder should impart smooth texture and disintegration 
characteristics to the system.  
5. Binders can either be liquid, semi solid, solid or mixtures of varying molecular weights 
such as polyethylene glycol. Commonly available fats such as cocoa butter and 
hydrogenated vegetable oils can also be used  
1.8 Various technologies used in the preparation of orodispersible tablets 2 
1.8.1 Direct compression4 
In this method, tablets are compressed directly from the mixture of the drug and excipients 
without any preliminary treatment. The mixture to be compressed must have adequate flow 
properties and cohere under pressure thus making pretreatment as wet granulation unnecessary. 
Few drugs can be directly compressed into tablets of acceptable quality. A type of disintegrant 
and its proportion are of prime importance. The other factors to be considered are particle size 
distribution, contact angle, pore size distribution, tablet hardness and water absorption capacity. 
All these factors determine the disintegration. The disintegrant addition technology is cost 
effective and easy to implement at industrial level 
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1.8.2 Addition of disintegrant5 
Microcrystalline cellulose, cross linked carboxymethyl cellulose sodium, cross linked polyvinyl 
pyrrolidone and partially substituted hydroxypropyl cellulose, though water insoluble, absorb 
water and swell due to capillary action and are considered as effective disintegrants in the 
preparation of first dissolving tablets. Fast disintegration of tablets can also be achieved by 
incorporating effervescent disintegrating agents, which generates carbon dioxide. This 
phenomenon also resulted in partial taste masking of unacceptable taste of the drug. The major 
drawback of effervescent excipients is their hygroscopicity (i.e., the ability to absorb 
atmospheric moisture). Hence, their manufacture requires control of humidity conditions and 
protection of the final product. This is reflected by the overall cost of the product.(Sharma et al)  
Table No. 1. Various commercially available superdisintegrants along with their properties in 
brief 
Sr 
no 
Name Type Properties Conc. Used 
(%) 
Brand name 
1. Crospovidone Polyvinyl-
pyrroli-
done  
Rapidly disperses and 
swells in water. 
0.5-5 Kollidon CL 
Polyplasdone 
XL 
2 Micro 
crystalline 
cellulose 
 
Micro 
crystalline 
cellulose 
 
Breaking the hydrogen  
bonding between adjacent 
bundles of cellulose 
microcrystals. 
 
10-20 
Avicel 
3. Croscarmellose 
sodium 
Modified 
cellulose 
Excellent swelling and 
water wicking properties. 
0.5-5 Ac-di-sol 
Primellose 
Solutab 
Other super disintegrants which are rarely used are: 
 Gellan Gum 
 Xanthan Gum 
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1.8.3 Sugar based excipients2 
Sugar based excipients are used for taste masking and as bulking agents. Most of the drugs are 
having unpleasant or bitter taste. The basic requirement for designing ODTs is that the drug 
should not have disagreeable taste so taste masking is necessary in most of the cases. Sorbitol, 
mannitol, xylitol, dextrose, fructose, isomalt, maltitol, polydextrose are mainly used. Aqueous 
solubility and sweetness impart a pleasing mouth feel and good taste masking. But not all sugar-
based materials have fast dissolution rate and good compressibility or compactability. However 
technologies are developed to make use of the sugar based excipients in the design of fast 
dissolving tablets. Other ingredients commonly used are water soluble diluents, lubricants, 
antistatic agents, plasticizers, binders, colors and flavors. Sugar-based excipients are classified 
into two types on the basis of their moldabilty and dissolution rate. Type I Saccharides (e.g. 
lactose and mannitol) exhibit low moldability but high dissolution rate.  Type II saccharides (e.g. 
maltose, maltitol) exhibit the high moldabilty but a low dissolution rate. Moldabilty in this 
respect defined as the capacity of the compound to be compressed. The moldability of Type I 
saccharides can be improved by granulating with it by type II Saccharides, This technology 
applied for rapidly disintegrating oral tablets that can effectively be manufactured by the 
crystalline transition of amorphous sucrose using the fluidized bed granulation method.  
1.8.4 Spray drying6 
A highly porous and fine powder is prepared by spray drying an aqueous composition containing 
support matrix and other components. This is then mixed with active ingredient and compressed 
into tablet  
1.8.5 Sublimation6 
The basis of this technique is to add inert solid ingredients that volatilize readily, e.g. camphor, 
ammonium bicarbonate, naphthalene, urea, urethane etc to other tablet excipients and the 
mixture is then compressed into tablets. Volatile material is then removed via sublimation, which 
generate a porous structure.  
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                                           Figure No1.3   Steps involved in sublimation 
1.8.6 Molding2 
Tablets prepared by this method are solid dispersions. Physical form of drug in the tablets 
depends on extent it dissolves in the wetted mass. The drug can exist as discrete particles or 
micro particles in the matrix. It can dissolve totally to form a solid solution or dissolve partially 
in the molten carrier and remaining, if any, stays undisclosed and dispersed in the matrix. 
Disintegration time, drug dissolution rate and mouth feel will depend on the type of dispersion. 
Different molding techniques can be used to prepare mouth dissolving tablets:  
1.8.6.1 Compression molding  
The powder mixture previously wetted with a solvent like ethanol/water is compressed into 
mould plates to form a wetted mass. 
 1.8.6.2 Heat molding 
A molten matrix in which drug is dissolved or dispersed can be directly molded into 
orodispersible tablets. 
1.8.6.3 Vacuum lyophilization  
This process involves evaporation of solvent from a drug solution or suspensions at a standard 
pressure. 
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Molded tablets posses porous structure, which facilitates rapid disintegration and easy 
dissolution. Molded tablets offer improved taste due to water soluble sugars present in dispersion 
matrix. But molded tablets lack good mechanical strength and can undergo breakage or erosion 
during handling and opening of blister packs. However, adding sucrose, acacia or polyvinyl 
pyrrolidone can increase mechanical strength. 
1.8.7 Freeze drying or lyophilization7 
Lyophilization can be used to prepare tablets that have very porous open matrix network into 
which saliva rapidly moves to disintegrate lyophilized mass after it is placed in mouth. The drug 
is entrapped in a water soluble matrix which is freeze dried to produce a unit which rapidly 
disperses when placed in mouth. Apart from the matrix and active constituents, the final 
formulation may contain other excipients, which improve the process characteristics or enhance 
the quality of final product. These include suspending agents, wetting agents, preservatives, 
antioxidants, colors and flavors. The preferred drug characteristics for freeze drying formulations 
are water insoluble, low dose, chemically stable, small particle size and tasteless. Lyophilization 
results in preparations, which are highly porous, with a very high specific surface area, which 
dissolve rapidly and show improved absorption and bioavailability.(US pat no.5,457,895) 
1.8.8 Mass extrusion8 
In this technique, a blend of active drug and other ingredients is softened using solvent mixture 
of water soluble polyethylene glycol, using methanol and then the softened mass is extruded 
through the extruder or syringe to get a cylinder of product, which is finally cut into even 
segments with the help of heated blades to get tablets. The dried cylinder can be used to coat the 
granules of bitter tasting drugs and thereby masking their bitter taste. 
1.8.9 Nanonization  
A recently developed Nano melt technology involves reduction in the particle size of drug to 
nano size by milling the drug using a proprietary wet milling technique. The nanocrystals of the 
drug are stabilized against agglomeration by surface adsorption on selected stabilizers, which are 
then incorporated into mouth dissolving tablets. This technique is especially advantageous for 
poorly water soluble drugs. Other advantages of this technology include fast 
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disintegration/dissolution of nanoparticles leading to increased absorption and hence higher 
bioavailability and reduction in dose, cost effective manufacturing process, conventional 
packaging due to exceptional durability and wide range of doses (up to 200 mg of drug per unit). 
1.8.10 Taste masking9 
Taste masking is an essential requirement for fast dissolving tablets for commercial success. 
Taste masking of the active ingredients can be achieved by various techniques:- 
microencapsulating into pH sensitive acrylic polymers, coating and fine granules of drug and 
disintegrant, coacervation using gelatin, using monoglycerides having a low melting point and by 
using ion exchange resin. Drug can be bound to the resin by either repeated exposure of the resin 
to the drug in a chromate graphic column or by prolonged contact of resin with the drug solution. 
Drugs are attached to the oppositely charged resin substrate, forming insoluble adsorbents or 
resonate through weak ionic bonding so that dissociation of the drug-resin complex does not 
occur under the salivary pH conditions. 
                          Table No. 1. 2: Marketed fast dissolving tablets 
Product A.P.I        Manufacturer 
Lamictal ODT Lam199 GlaxoSmithKline 
Felden fast melt Piroxicam Pfizer Inc., NY, USA 
Zyprexia Olanzapine Eli Lilly, Indianapolis., USA 
Pepcid RPD Famotidine Merck and Co., NJ, USA 
Claritin Redi Tab Loratidine Schering Plough Corp., USA 
Zoming-ZMT Zolmitriptan AstraZeneca, Wilmington, USA 
Romilast Montelukast Ranbaxy Lab. Ltd., India 
Olanex Instab Olanzapine Ranbaxy Lab. Ltd., India 
Torrox MT Rofecoxib Torrent Pharmaceuticals., India 
Nimulid MDT Nimesulide Panacea Biotech., India 
Febrectol Paracetamol Prographarm, Chateauneuf, France 
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                        Table No1.3: Patented Technologies for Mouth dissolving tablets 
Formulation Key attributes Company 
Zydis® Freeze-drying on blister packing RP Scherer (Cardinal) 
Lyoc Freeze-drying on the shelves of freeze dryer Laboratories L. Lafon, 
Maisons Alfort, France
Flashtab Granulation of excipients by wet or dry 
granulation and compressing into tablets 
Ethypharm France. 
OraSolv low compression force and an effervescent
couple as a water-soluble disintegrating 
agent 
Cima Labs Inc. 
DuraSolv Direct compression using water-soluble 
excipients 
Cima Labs Inc. 
WOWTAB® High- and low-moldability saccharides Yamanouchi Pharma 
Pharmabrust Direct compression of powder mixture SPI Pharma 
Advantol™ 
200 
Directly compressible excipient system SPI Pharma 
Advatab® Direct compression using external
lubrication system 
Eurand 
Microcaps mask the bitter taste Apatalis 
 
Orally disintegrating formulations are required in diseases or disorders where the onset of action 
required is very fast like cardiac ischemia, hyper tension, head ache, tachycardia, bradycardia  
anti psychotic, anti depressants, migraine. 
Zeplar TM Selegilline Amarin Corp., London, UKBristol  
Tempra Quiclets Acetaminophen Bristol Myers Squibb, NY, USA 
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1.9 Migraine 
The typical migraine headache is unilateral (affecting one half of the head) and pulsating in 
nature and lasting from two to 72 hours; symptoms include nausea, vomiting, photophobia 
(increased sensitivity to light) and phonophobia (increased sensitivity to sound) the symptoms 
are generally aggravated by routine activity. Approximately one-third of people who suffer from 
migraine headaches perceive an aura transient visual, sensory, language, or motor disturbances 
signaling the migraine will soon occur. Initial treatment is with analgesics for the headache, an 
antiemetic for the nausea, and the avoidance of triggers. The cause of migraine headache is 
unknown; the most supported theory is that it is related to hyper excitability of the cerebral 
cortex and/or abnormal control of pain neurons in the trigeminal nucleus of the brainstem. 
Propensity to migraine headache sometimes disappears during pregnancy, but in some women, 
migraines may become more frequent. Preventive migraine drugs are considered effective if they 
reduce the frequency or severity of migraine attacks by at least 50%.The major problem with 
migraine preventive drugs, apart from their relative inefficacy, is that unpleasant side effects are 
common. So, preventive medication is limited to patients with frequent or severe headaches.  
Many medicines are available to prevent or reduce frequency, duration and severity of migraine 
attacks. They may also prevent complications of migraine. Beta blockers, such as Propranolol, 
atenolol, and metoprolol; calcium channel blockers, such as amlodipine, flunarizine and 
verapamil; the anticonvulsants sodium valproate, divalproex, gabapentin and topiramate; and 
tricyclic antidepressants are some of the commonly used drugs.  
Tricyclic antidepressants have been found to be more effective than SSRIs Tricyclic 
antidepressants have been long established as efficacious prophylactic treatments. These drugs, 
however, may give rise to undesirable side effects, such as insomnia, sedation or sexual 
dysfunction. There is no consistent evidence that SSRI antidepressants are effective for migraine 
prophylaxis. While amitryptiline (Elavil) is the only tricyclic to have received FDA approval for 
migraine treatment, other tricyclic antidepressants are believed to act similarly and are widely 
prescribed, often to find one with a profile of side effects that is acceptable to the patient In 
addition to tricyclic a, the antidepressant nefazodone may also be beneficial in the prophylaxis of 
migraines due to its antagonistic effects on the 5-HT2A] and 5-HT2C receptors It has a more 
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favorable side effect profile than amitriptyline, a tricyclic antidepressant commonly used for 
migraine prophylaxis. Antidepressants offer advantages for treating migraine patients with 
comorbid depression selective seretonine reuptake inhibitor (SSRIs) are not approved by the 
FDA for treatment of migraines, but have been found to be effective by some practitioners 
 
1.10 EMRB04210, 11, 12 
EMRB042 is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute 
treatment of migraine attacks with or without aura in adults. EMRB042is not intended for the 
prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. 
EMRB042is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a 
member of the 5-HT1D family) having only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 
receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 
receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, 
or benzodiazepine receptors. This action in humans correlates with the relief of migraine 
headache. In addition to causing vasoconstriction, experimental data from animal studies show 
that EMRB042also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve 
innervating cranial blood vessels, which may also contribute to the antimigrainous effect of 
EMRB042in humans. It binds to 5-HT IB/ID receptors, resulting in cranial vessel vasocontriction, 
inhibition of neuropeptide release, and reduced transmission in trigeminal pain pathways. 
Completely absorbed after PO use; rate of absorption of Mxlt-MLT is somewhat slower. Peak 
plasma levels, 1-1.5 hr; Mxlt-MLT: 1.6-2.5 hr. Food has no effect on bioavailability, but will 
delay time to reach peak levels by an hr. t 1/2: 2-3 hr. Metabolized by MAO-A; most is excreted 
through the urine is a significant first-pass effect.  
1.11 clinical applications11 
Acute treatment of migraine attacks in adults with or without aura.  
Contraindications: Use in children less than 18 years of age, as prophylactic therapy of migraine, 
or use in the management of hemiplegic or basilar migraine. Use in those with ischemic heart 
disease or vasospastic coronary artery disease, uncontrolled hypertension, within 24 hr of 
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treatment with another 5-HT 1 agonist or an ergotamine-containing or ergot-type medication 
(e.g., dihydroergotamine, methysergide). Use concurrently with MAO inhibitors or use of 
EMRB042within 2 weeks of discontinuing a MAO inhibitor. Strongly recommended the drug 
not be given in unrecognized coronary artery disease (CAD) predicted by the presence of risk 
factors, including hypertension, hypercholesterolemia, smoking, obesity, diabetes, strong family 
history of CAD, female with surgical or physiological menopause, or males over 40, unless a CV 
evaluation reveals the client is free from CAD or ischemic myocardial disease.  
  
1.12 A.P.I dosage11 
Orally disintegrating Tablets- 5mg, 10mg. 
Adults: Single dose of 5 mg or 10 mg. Doses should be separated by at least 2 hr, with not more 
than 30 mg taken in any 24-hr period. 
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2 LITERATURE REVIEW 
1) Josel S. et al.developed orodispersible tablet of promethazine theoclate by direct compression 
using superdisintegrant combinations and subliming materials. Aqueous solubility of 
Promethazine theoclate is poor and thus late onset of action is observed. Formulations were 
developed using superdisintegrants (crosspovidone, CP and sodium starch glycolate, SSG) and 
co-processed superdisintegrants (CP: SSG 3:1, CP:SSG 1:1, CP:SSG 1:3) in different 
concentrations. After examining the flow properties of the powder blends, it was subjected to 
tablet compression. Prepared tablets were evaluated for thickness, hardness, friability, 
disintegration time, wetting time, water absorption ratio, weight variation, percentage drug 
content, invitro disintegration time, uniformity of dispersion and invitro dissolution studies. 
formulation containing CP: SSG 3:1 at a concentration 5% was found to be promising and 
selected as the optimized formulation. A similar formulation was prepared by sublimation 
technique and compared with the optimized formulation. This comparative evaluation revealed 
that direct compression method is a better alternative to sublimation method. It was concluded 
that dissolution rate of Promethazine theoclate can be enhanced to a great extent by direct 
compression technique with the addition of novel co-processed superdisintegrants which give 
immediate relief from emesis. 
 
2) Patel T. et al developed a formulation containing topiramate, it is an anti-epileptic drug used 
to treat partial onset seizures, or primary generalized tonicclonic seizures in children and adults. 
But it’s bitter in taste, and there is a critical need which to mask the taste. Different types of ion 
exchange resins like Kyron T-104, Kyron T-114, Kyron T-134, Doshion P 542 were used to 
form complex with Topiramate. Ion exchange resin to drug ratio, effect of pH, effect of 
temperature, effect of resin soaking time, effect of stirring time on complex formation were 
optimized. Drug and resin complex was evaluated for swelling, particle size analysis and drug 
release from drug and resin complex. So developed taste masked drug become eligible to 
formulate mouth disintegrating dosage form which was not a good candidate for orodispersible 
formulation before. 
 
3) Adel M et al developed glimepiride (1 mg) rapidly disintegrating tablets (RDT) by direct 
compression, and also, evaluated Pharmaburst as a newly introduced diluent for this type of 
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tablets, either alone or in combination with other well known tablet excipients. Another goal was 
to study the stability, as well as, the in vivo effects of selected formulations. Orange flavor was 
the most preferred flavor for the prepared rapidly disintegrating tablets containing Pharmaburst 
as a single diluents. Pharmaburst alone is sufficient to produce rapidly (orally) disintegrating 
tablets of glimepiride with good physical characteristics, better compactability and shorter invivo 
and invitro disintegration time. The prepared Glimepiride RDT were found to have faster onset 
of action than the conventional glimepiride tablets. Also, they were effective in lowering fasting 
blood glucose levels (FBG) in rabbits. glimepiride RDT containing Pharmaburst alone were 
found to be stable when subjected to accelerated stability conditions (40 °C / 75 % relative 
humidity) for at least 3 months. Packaging the prepared Glimepiride RDT in 40 CC high density 
polyethylene (HDPE) bottles with 2 grams silica gel desiccant canisters and rayon had provided 
sufficient protection for the tablets. The used packaging system is believed to be very practical 
and convenient for elderly diabetic patients. It is also assumed to be preferred by the 
manufacturers. 
 
4) JAIN C et al developed fast dissolving tablets of valsartan using different superdisintegrants 
by direct compression method. FDTs were evaluated for physicochemical properties and in vitro 
dissolution. Effect of disintegrant on disintegration behaviour of tablet in artificial saliva, pH 5.8 
was evaluated. Wetting time of formulations containing Crospovidone was least and tablets 
showed fastest disintegration. The drug release from FDTs increased with increasing 
concentration of superdisintegrants and was found to be highest with formulations containing 
Crospovidone. The release of valsartan from FDTs was found to follow non-Fickian diffusion 
kinetics. 
 
5) Patil M. et al developed teast masked the intensely bitter taste of tramadol hydrochloride and 
developed a orally disintegrating tablets for achievement of quick onset of action of the drug. 
Eudragit E 100 was used as a taste masking agent. Mass extrusion was the technique used for 
preparing taste masked granules and tablet was prepared with using superdisintegrants like 
crosspovidone, croscarmellose sodium and sodium starch glycolate, and evaluated for the pre-
compression parameters such as bulk density, compressibility, angle of repose etc. The prepared 
batches of tablets were evaluated for hardness, weight variation, friability, drug content, 
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disintegration time and in-vitro dissolution profile and found satisfactory. Among the 
formulations containing Crosspovidone was least and tablets showed fastest disintegration. The 
drug release from orally disintegrating tablets increased with increasing concentration of 
superdisintegrants and was found to be highest with formulations containing Crosspovidone. 
Thus results conclusively demonstrated successful masking of taste and fastest disintegration of 
the formulated tablets in oral cavity. 
 
6) Prajapati B et al formulated directly compressible orally disintegrating tablets of Cinnarizine 
with sufficient mechanical integrity, content uniformity, and acceptable palatability to assist 
patients of any age group for easy administration. Effect of varying concentrations of different 
superdisintegrants such as crosspovidone, croscarmellose sodium, and sodium starch glycolate 
on disintegration time was studied. The disintegration time of the optimized CP5 batch was 25 
sec. Good correlation was observed between disintegration time and water absorption ratio (R) 
for each of three superdisintegrants at concentrations studied. Considering the ‘R’ values and 
disintegration time, crosspovidone was significantly superior compared to other two 
superdisintegrants tested. Release of drug was faster from formulations containing 6% 
crosspovidone (CP5) compared to the marketed conventional Cinnarizine tablet. Differential 
scanning calorimetric studies did not indicate any excipient incompatibility, either during mixing 
or after compression. It concluded that directly compressible orally disintegrating tablets of 
cinnarizine with lower friability, acceptable taste, and shorter disintegration times were obtained 
using crospovidone at optimized concentrations. 
 
7) Kannuri R et al developed a orally disintegrating tablets of escitalopram oxalate. 
Escitalopram oxalate is a selective serotonin reuptake inhibitor. The aim was to formulate orally 
disintegrating tablets of escitalopram oxalate using different ratios of Superdisintegrants LHPC 
21, Kyron and crosspovidone, while microcrystalline cellulose, mannitol, prosolv ODT used as 
fillers. Tablets were prepared by direct compression method. The tablets were evaluated for 
hardness, thickness, friability, and weight variation and disintegration time, dispersion times and 
% drug release studies were performed. Tablets containing Crosspovidone, Kyron as 
disintegrants and mannitol as filler showed the best results and were disintegrated rapidly within 
20 sec and 100% drug release was observed in 5mins. 
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8) Himabindu S. et al developed and evaluated oral disintegrating tablets (ODT) of metoprolol 
tartrate using super disintegrants, sodium starch glycolate, cross carmellose sodium and cross 
povidone in various diluents. Formulations F1 to F12 were prepared with various super 
disintegrants by using mannitol as diluent. From these formulations tablets prepared with cross 
povidone showed good release profiles. Formulations F13 to F16 were prepared by using cross 
povidone as super disintegrant and spray dried lactose as diluent and formulations F17 to F20 
were prepared by using cross povidone as super disintegrant and dibasic calcium phosphate as 
diluent. Based on disintigration time and in vitro drug release profile F14 was selected as 
optimized formulation. Formulating as an ODT resulted in rapid onset of action as the tablets 
disintegrate in less than a minute. Taste masking which is an important aspect of ODT 
formulation is achieved by using the sweetener aspartame. No chemical interaction between drug 
and excipients was confirmed by FTIR studies. 
 
9) Kakade S et al formulated orally disintegrating tablets of sertraline to achieve a better 
dissolution rate and further improving the bioavailability of the drug. Orally disintegrating 
tablets prepared by direct compression and using super disintegrants like crospovidone, 
croscarmellose sodium and sodium starch glycolate designate, designated as three different 
groups of formulation (A, B and C) respectively were prepared and evaluated for the 
precompression parameters such as bulk density, compressibility, angle of repose etc. The 
prepared batches of tablets were evaluated for hardness, weight variation, friability, drug content, 
disintegration time and in-vitro dissolution profile and found satisfactory. Among the three 
groups, group (C) containing crospovidone emerged as the best formulation and showed 
maximum dissolution rate with 98.49% drug release in 15 min. All three groups of formulations 
released the drug at faster rates than that of marketed conventional tablets of sertraline. 
 
10) Balasubramaniam J. et al conducted study to evaluate the effect of crospovidone, 
croscarmellose sodium, and sodium starch glycolate on the dissolution rates of poorly soluble 
drugs with varying aqueous solubility which showed crospovidone type B to provide the fastest 
rate of dissolution for poorly soluble drugs. The fact that tablet strength and disintegration times 
for the tablets containing each drug and all the superdisintegrant studies showed that tablet 
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hardness and disintegration did not influence dissolution. Crospovidone type B has unique 
chemistry, particle size, and particle morphology that result in high interfacial activity, which 
significantly aids dissolution. 
 
11) Rangole U. et al formulated rapidly disintegrating tablets by direct compression technology 
using hydrochlorothiazide as a model drug. Fast disintegrating tablet of hydrochlorothiazide was 
formulated using different concentration (2%, 3%, 4% and 5%) of superdisintegrants like 
Croscarmellose sodium and Crospovidone. All the batches were prepared by direct compression 
method using the Cadmach Single punch tablet compression machine using 8 mm flat punch. 
Disintegration time and drug release were taken as the basis to optimize the rapidly 
disintegrating tablet. Prepared tablets were evaluated for thickness, hardness, friability, 
uniformity of weight, disintegration time, wetting time and dissolution study. Crospovidone in 
the concentration of 4 % gives fasted disintegration in 16 sec. and shows 100% drug release 
within 14 min. is selected as the optimized formulation. Optimized formulation was subjected to 
stability studies for thirty days which showed stability with regards to release pattern. 
 
12) Paul Y et al developed oral dispersible tablets (ODTs) of zidovudine, an antiretroviral drug, 
using different superdisintegrants viz. Crospovidone (PPXL), Crosscarmellose sodium           
(Ac-di-sol) and sodium starch glycolate by direct compression method. The effects of 
disintegrants in different concentration on the release profile of zidovudine ODTs were studied. 
Developed ODTs were studied for their physicochemical properties and invitro drug release 
profile. The studied parameters were found to be satisfactory for all ODT formulations of 
zidovudine. Disintegration times of all formulations were found to be less than 60 seconds. 
Disintegration time decreased with increase in disintegrant concentration. ODTs prepared using 
Ac-di-sol 6% possessed least disintegration time, offered better dissolution profile than that of all 
the ODTs formulations developed in the present investigation and that of marketed conventional 
tablet formulation of zidovudine. Ac-di-sol when tried in concentration above 6% resulted in an 
increase in disintegration time instead of further decreasing it. Accelerated studies proved that 
the optimized formulation was stable even after 3 months. 
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13) Kinchi et al formulated orally disintegrating tablets of solbutamol sulphate using direct 
compression technology by employing directly compressible fillers such as mannitol and 
microcrystal cellulose, varying concentrations of super disintegrants as Ac-di-sol, primogel, and 
polyplasdone XL in  2%, 3%,  4%,  5%. Formulations were evaluated for hardness, weight 
variation, friability, drug content, disintegration time and in-vitro dissolution profile study. All 
the formulations showed the satisfactory i.e disintegration within one min and complete release 
in three min. A4 and A8 were prepared with concentration of ac-di-sol less than 5% showed 
100% release within 2 mins and 3 mins respectively, while 100% drug release of marketed 
conventional tablets was achieved in 25 min. which was much higher for the orally disintegrating 
tablets.  
 
14) Parikh R. et al developed ordispersible tablet of atenolol. Tablets containing atenolol 
camphor, kyron –T 314 and lactose were prepared by direct compression method. Camphor was 
sublimated by the exposure of the tablet to vacuum. Tablets were evaluated for the hardness, 
thickness, friability, weight variation, drug content, weight uniformity, water absorption ratio,   
in vitro dispersion time, invitro disintegration time, invitro dissolution profile. In investigation 32 
full factorial design was employed to investigate joint effect of two variables. Amount of 
camphor and kyron –T 314.The result of multiple linear regression analysis revealed that, for 
obtaining the rapid disintegration tablet should be prepared using optimum concentration of the 
camphore, and higher concentration of the kyron-T 314. A response surface plot presented 
graphically to represent the effect of independent variables on disintegration time, and 
percentage friability.  
 
15) Senthil k et al formulated the fast dissolving tablets of metprolol tartrate to achieve better 
bioavailability of the drug. These formulations were prepared with varying concentrations of the 
disintegrants 4%, 5%, 6% of such as Crospovidone (PPXL), Crosscarmellose sodium (Ac-di-sol) 
and pregelatinised starch, alone with directly compressible mannitol to enhance mouth feel. The 
prepared tablets were evaluated for hardness, thickness, friability, weight variation, drug content, 
weight uniformity, water absorption ratio in vitro dispersion time, invitro disintegration time, 
invitro dissolution profile. Among the nine formulations F9 was found to be satisfactory, which 
showed the maximum dissolution of 99.67% in 8 minutes.   
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                                                    3AIM AND OBJECTIVES 
3.1 Need for orally disintegrating formulation system:- 
EMRB042 is indicated for the acute treatment of migraine attacks with or without aura in adults. 
These conditions require a delivery system capable of delivering the drug rapidly for immediate 
relief. EMRB042 is rapidly and fully absorbed on oral administration but the absolute oral 
bioavailability is about 45% and Tmax is achieved at about 1 to 1.5hrs with oral administration 
suggesting a need for a delivery system with rapid achievement of Tmax. Orodispersible 
formulation can be considered as a solution to the above mentioned problem. 
Thus the primary objectives were 
1) Preformulation studies 
2) To select appropriate ingredients and disintegrant on dissolution rate of orodispersible 
formulation. 
3) To Prepare Orodispersible tablets of EMRB042 using direct compression technique. 
4) To evaluate and characterize the prepared formulations. 
5)  Stability studies of prepared formulation. 
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                                                       4 PLAN OF WORK 
4.1 Selection and Procurement of Drug and Excipients: 
4.2 Preformulation Studies 
• Evaluation of marketed formulation. 
• Drug interaction studies. 
• Spectral Analysis of EMRB042. 
4.3 Selection of appropriate ingredients and disintegrant for orodispersible formulation. 
4.4 Formulation of Tablet 
• Direct Compression Method 
• Wet granulation method 
4.5 Evaluation of Powder Blend 
• Bulk Density 
• Taped Density 
• Carr’s Index 
• Hausner’s Ratio 
• Angle of Repose 
4.6 Evaluation of Tablets 
• Hardness 
• Thickness 
• Friability 
• Weight Variation 
• Uniformity of Content 
• InVitro Disintegration Test 
• InVitro Dissolution Test 
• Assay of test product 
4.7 Stability studies of prepared formulation. 
• InVitro Dissolution Test 
4.8 Comparison of the optimized formulation with conventional marketed tablet of 
EMRB042.  
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5 MATERIALS AND EQUIPMENTS 
5.1 EQUIPMENTS 
Table no.5.1 Equipments list 
Sr. no. Name of Equipment Manufacturer 
1 Rapid Mixer Granulator Anchor mark Pvt. Ltd. 
2 Rapid dryer Retsch 
3 Multi mill Anchor mark Pvt.Ltd. 
4 Moisture balance Mettler Toledo 
5 Double cone blender SSPM Eng. System 
6 Compression machine (16 station) Cadmach  
7 Friability tester Electro lab 
8 Hardness tester Pharmg harness tester 
9 Weighing Balance Mettler Toledo 
10 Tap density tester Electrolab 
11 Electromagnetic sieve shaker Electrolab 
12 Sieve Electropharma 
13 Malvern Mastersizer 2000 Malvern Mastersizer 2000 
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5.2 Innovator details 
Table no.5.2 Innovator details 
 
 
 
                                                     
 
 
INNOVATOR DETAILS 
EMRB042 orally disintegrating Tablets 
Generic name MXLT 
Company Merck & Co., Inc. 
RLD 10 mg 
Strength 5 / 10 mg 
Label claim Each Tablet contains EMRB042 10mg 
Composition Gelatin, Mannitol, Glycine ,Aspartame ,Peppermint flavor 
Packing Blister:-  pealable blister having single tablets  structure  of blister 
Thickness (mm) 10.0-11.5 mm (side-to-side) 
Storage condition 
Protect from excessive heat and humidity. Dispense in a tight 
container with child-resistant closure (as required). 
Snaps 
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5.3 Excipients 
  Table no.5.3 Excipients 
Sr. 
No 
name of 
Ingredient 
Compendial 
Status 
Trade name Source Use 
1. EMRB042 USP  Matrix A.P.I 
2. Mannitol USP 
Pearlitol SD 
200 
Roquett-
Pharma 
Diluent 
3. 
Microcrystalline 
 
USP 
 Avicel 
PH101 
F.M.C-Bio 
polymer 
Diluent 
4. 
Crospovidone 
 
USP 
Polyplasdone 
ultra 
I.S.P Binder 
5 
Calcium Silicate 
 
USP Hubersorb 
J.M.Huber 
Corp 
Anti caking 
agent 
6 
Croscarmellose 
Sodium 
USP Ac-di-sol 
F.M.CBio 
polymer 
Disintegrant 
7 Ludiflash USP Ludiflash B.A.S.F Filler 
8 
Colloidal 
Silicon Dioxide 
USP Aerosil-200 evonik Glidant 
9 Aspartame USP - 
    Neutra 
weet 
Sweetener 
11 
Sodium 
Stearyl Fumarate 
USP Pruv J.R.S Lubricant 
12 
Magnesium 
Stearate 
USP Veg grade Merck Lubricant 
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5.4   DRUG PROFILE10, 11, 12 
 EMRB042 
5.4.1 Molecular weight- 391.4 
5.4.2 Chemical Formula- C15H19N5 
5.4.3 Category‐ Antimigraine  
5.4.4 Indications 
EMRB042 is indicated to relieve acute migraine headaches (with or without aura).Headache, 
migraine 
5.4.5 Organoleptic characteristics 
Colour-White crystalline powder  
Odour-odorless  
Taste- bitter in taste 
5.4.6 Mechanism of action 
EMRB042's mechanism of action has not been established. It is thought that agonist activity at 
the 5-hydroxytryptamine (5-HT) 1B and 5-HT 1D receptor subtypes provides relief of headache. 
EMRB042 is a highly selective agonist at these receptor subtypes; it has no significant activity at 
5-HT 2 or 5-HT 3 receptor subtypes or at adrenergic, dopaminergic, histamine, muscarinic, or 
benzodiazepine receptors. It has been proposed that constriction of cerebral vessels resulting 
from 5-HT 1B/1D receptor stimulation reduces the pulsation that may be responsible for the pain 
of migraine headaches. It has also been proposed that EMRB042 may relieve migraine. 
5.4.7 Absorption 
Oral bioavailability is 45% Food has no effect on the bioavailability of EMRB042. However, 
administering EMRB042 with food will delay by 1 hour the time to reach peak plasma 
concentration. The rate of absorption is not affected by the presence of a migraine attack.  
5.4.8 Protein binding 
Low (14%) 
5.4.9 Biotransformation 
EMRB042 is metabolized by monoamine oxides A isoenzyme (MAO-A) to an inactive indole 
acetic acid metabolite. In addition, several other inactive metabolites are formed. An active 
metabolite, N-monodesmethyl-EMRB042, with pharmacological activity similar to that of the 
parent compound has been identified in small concentrations (14%) in the plasma. 
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5.4.10 Half life 
Approximately 2 to 3 hours  
5.4.11 Elimination 
Approximately 82% and 12% of the dose was excreted in the urine and feces, respectively within 
120 hours. Approximately 14% of EMRB042 was excreted in  urine as unchanged and 51% as 
an indole acetic acid metabolite 
5.4.12 Mutagencity 
EMRB042 demonstrated no mutagenic or clastogenic effects in the microbial mutagenesis assay 
or in the invitro studies, including mammalian cell. 
5.4.13 Fertility 
A fertility study in female rats receiving oral doses of EMRB042 of up to 100 mg/kg per day 
approximately 225 times the AUC in humans receiving the maximum recommended human dose 
found changes in estrus cyclicity and delays in time to mating. The no effect dose was 10 mg/kg 
per day Also, a reproductive study in male rats receiving 250 mg/kg per day found no 
impairment. 
5.4.14 Pregnancy 
Trials have not been done in pregnant women. A reproductive study in female rats receiving 
doses of EMRB042 of up to 10 and 100 mg/kg per day prior to and during mating and 
throughout gestation and lactation found reduced birth weights and pre and post weaning weight 
gain in the offspring of the rats.. Although there was no apparent maternal toxicity, 
developmental effects on offspring growth occurred. FDA Pregnancy Category is C. 
5.4.15 Breast feeding 
It is not known whether EMRB042 is distributed into human breast milk. 
5.4.16 Geriatrics 
Pharmacokinetic studies are not demonstrated. Geriatric specific problems that would limit the 
use of EMRB042 in geriatric patients older than 65 years of age, there was no difference in 
efficacy or overall side effects compared with younger adult. 
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5.2Excipients 
5.2.1 Ludiflash 
Ludiflash is composed of the following 
90% Mannitol (Mannitol: EP, USP, JP) 
Fast dissolving filler with a mildly Sweet taste 
 
5% Kollidon® CL-SF5 (Crospovidone) (Kollidon CL-SF: EP, USP, JPE) 
A superior tablet disintegrant Highly effective, disintegrates the tablet in the presence of very 
little liquid Offers a pleasantly smooth and Creamy mouth feel 
 
5% Kollicoat (Kollicoat SR 30D: EP) 
                                              Hydrophobic binder for enhanced disintegration                                                     
 
                                            With Ludiflash, a hard tablet disintegrates 
 
                                             It disintegrates completely to form a fine cream.                                                    
 
                                            The highly porous tablet disintegrates very quickly 
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5.2.2 Microcrystalline cellulose13, 14                               
Synonyms Avicel PH; Cellets; Celex; cellulose gel; hellulosum 
microcristallinum; Celphere; Ceolus KG; crystalline cellulose 
Functional Category. Adsorbent; suspending agent; tablet and capsule diluent; 
tablet disintegrant 
Loss on drying Not more than 7% 
Density (true)  1.512–1.668 g/cm3 
Solubility  Slightly soluble in 5% w/v sodium hydroxide solution; 
practically insoluble in water, dilute acids, and most organic 
solvents. 
Stability and Storage 
Conditions 
Microcrystalline cellulose is a stable though hygroscopic 
material. The bulk material should be stored in a well-closed 
container in a cool, dry place 
Incompatibilities. Microcrystalline cellulose is incompatible with strong 
oxidizing agents 
Applications Microcrystalline cellulose is widely used in pharmaceuticals, 
primarily as a binder/diluent in oral tablet and capsule 
formulations where it is used in both wet-granulation and 
direct-compression processes.  In addition to its use as a 
binder/diluent, microcrystalline cellulose also has some 
lubricant and disintegrant properties that make it useful in 
tabletting 
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5.2.3 Croscarmellose sodium15, 16 
Synonyms Ac-Di-Sol; crosslinked carboxymethylcellulose sodium; 
Explocel; modified cellulose gum, Nymcel ZSX; Pharmacel XL; 
Primellose; Solutab; Vivasol. 
Chemical Name Cellulose, carboxymethyl ether, sodium salt 
Functional Category Tablet and capsule disintegrant. 
Solubility Insoluble in water, although croscarmellose sodium rapidly 
swells to 4–8 times its original volume on contact with water. 
Practically insoluble in acetone, ethanol and toluene. 
Density 1.543 g/cm3  
Stability and Storage 
Conditions 
CCS is a stable though hygroscopic material.A model tablet 
formulation prepared by direct compression, with CCS as a 
disintegrant, showed no significant difference in drug dissolution 
after storage at 30°C for 14 months. CCS should be stored in a 
well-closed container in a cool, dry place. 
Incompatibilities The efficacy may be slightly reduced in tablet formulations by 
process that contain hygroscopic excipients such as sorbitol, CCS 
is not compatible with strong acids or with soluble salts of iron 
and some other metals such as aluminum, mercury, and zinc. 
Applications CCS is used as disintegrant for capsules,tablets, and granules. In 
tablet formulations, CCS may be used in both direct-compression 
and wet-granulation processes. In wet granulations, the CCS 
should be added in both wet and dry stages of the process for 
wicking and swelling .CCS at concentrations up to 5% w/w may 
be used as a tablet disintegrant. 
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5.2.4 Mannitol 17, 18 
Synonyms Cordycepic acid;  manna sugar;D-mannite; mannite; Mannogem; 
Pearlitol. 
Chemical Name D-Mannitol 
Functional Category Diluent; diluent for lyophilized preparations; sweetening agent; 
Tablet and capsule diluent; tonicity agent 
Solubility Alkalis                Soluble 
Ethanol (95%)  1 in 83 
Ether                  Practically  insoluble 
Glycerin            1 in 18 
Propan-2-ol      1 in 100 
Water                1 in 5.5 
Density Density (true): 1.514 g/cm3 
Stability and Storage 
Conditions 
Stable in the dry state and in aqueous solutions. In solution, 
mannitol is not attacked by cold, dilute acids or alkalis, nor by 
atmospheric oxygen in the absence of catalysts. Does not undergo 
Millard reactions. The bulk material should be stored in a well-
closed container in a cool, dry place. 
Incompatibilities Mannitol solutions, 20% w/v or stronger, may be salted out by 
Potassium chloride or sodium chloride. Precipitation has been 
reported to occur when a 25% w/v mannitol solution was allowed 
to contact plastic. 
Applications Used as a diluent (10–90% w/w) in tablet formulations, it is not 
hygroscopic and may thus beused with moisture-sensitive active 
ingredient, used in direct-compression tablet applications, for 
which the granular and spray-dried forms are available, or in wet 
granulations. Granulations with mannitol have the advantage of 
being dried easily. Tablet applications include antacid 
preparations, glyceryl  trinitrate tablets, and vitamin preparations. 
As an excipient in the manufacturing of chewable tablet 
formulations because of its negative heat of solution, 
Sweetness, and ‘mouth feel’ 
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5.2.5 Crosspovidone19, 20 
Synonyms Crosslinked povidone; E1202; Kollidon CL; Kollidon CL-M; 
Polyplasdone XL; Polyplasdone XL-10; 
polyvinylpolypyrrolidone; 
PVPP; 1-vinyl-2-pyrrolidinone homopolymer. 
Chemical Name 1-Ethenyl-2-pyrrolidinone homopolymer 
Functional Category Tablet disintegrant. 
Solubility Practically insoluble in water and most common 
Organic solvents. 
Density 1.22 g/cm3 
Stability and Storage 
Conditions 
Since crospovidone is hygroscopic, it should be stored in an 
Airtight container in a cool, dry place 
Incompatibilities Crospovidone is compatible with most organic and inorganic 
Pharmaceutical ingredients. When exposed to a high water 
Level, crospovidone may form molecular adducts with some 
Materials 
Applications Crospovidone is a water-insoluble tablet disintegrant and 
dissolution agent used at 2–5% concentration in tablets prepared 
by direct-compression or wet and dry granulation methods. It 
rapidly exhibits high capillary activity and pronounced hydration 
capacity, with little tendency to form gels. Particle size of 
strongly influences disintegration of analgesic tablets. Larger 
particles provide a faster disintegration than smaller particles. 
Used as a solubility enhancer. With the technique of co-
evaporation, Used to enhance the solubility of poorly soluble 
drugs. The drug is adsorbed on crospovidone in the presence of a 
suitable solvent and the solvent is then evaporated. This 
technique results in faster dissolution rate. 
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5.2.6 Colloidal Silicon Dioxide21, 22 
 
                           
Synonyms Aerosil; Cab-O-Sil; Cab-O-Sil M-5P; colloidal silica; fumed 
Silica; light anhydrous silicic acid; silicic anhydride; silicon 
Dioxide fumed; Wacker HDK. 
Chemical Name Silica 
Functional Category Adsorbent; anticaking agent; emulsion stabilizer; glidant; 
Suspending agent; tablet disintegrant; thermal stabilizer; 
Viscosity-increasing agent 
Solubility Practically insoluble in organic solvents, water, and acids, except 
hydrofluoric acid; soluble in hot solutions of alkali hydroxide. 
Forms a colloidal dispersion with water. 
Density 0.029–0.042 g/cm3 
Stability and Storage 
Conditions 
Colloidal silicon dioxide is hygroscopic but adsorbs large 
quantities of water without liquefying. When used in aqueous 
systems at a ph 0–7.5, colloidal silicon dioxide is effective in 
increasing the viscosity of a system. However, at a ph greater 
than 7.5 the viscosity-increasing properties of colloidal silicon 
dioxide are reduced; and at a ph greater than 10.7 this ability is 
lost entirely since the silicon dioxide dissolves to form silicates. 
Colloidal silicon dioxide powder should be stored 
In a well-closed container. 
Incompatibilities Incompatible with diethylstilbestrol  preparations 
Applications Used in pharmaceuticals, cosmetics, and food products, Its small 
particle size and large specific surface area give it desirable flow 
characteristics 
That are exploited to improve the flow properties of dry powders 
in a number of processes such as tablet .Used to stabilize 
emulsions. And as a thixotropic thickening and suspending agent 
in gels and semisolid preparations. With other ingredients of 
similar Refractive index, transparent gels may be formed.  
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5.2.7 Sodium Stearyl Fumarate23, 24 
Synonyms 
 
Fumaric acid, octadecyl ester, sodium salt; Pruv; sodium 
Monostearyl Fumarate 
Chemical Name 2-Butenedioic acid, monooctadecyl ester, sodium salt 
Molecular Weight 390.5 
Density  1.107 g/cm3 
Functional Category Tablet and capsule lubricant 
Solubility  Acetone          Practically insoluble 
Chloroform     Practically insoluble 
Ethanol           Practically insoluble 
Methanol        Slightly soluble 
Water              1 in 20 000 at 258C 
                        1 in 10 at 808C 
                        1 in 5 at 908C 
Stability and Storage 
Conditions 
At ambient temperature, sodium stearyl fumarate is stable for 
Up to 3 years when stored in amber glass bottles with 
Polyethylene screw caps. 
The bulk material should be stored in a well-closed 
Container in a cool, dry place. 
Incompatibilities Sodium stearyl fumarate is reported to be incompatible with 
Chlorhexidine acetate. 
Application Sodium stearyl fumarate is used as a lubricant in capsule and 
Tablet formulations at 0.5–2.0% w/w concentration.(1–9) It is 
Also used in certain food applications 
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5.2.8 Magnesium Stearate25, 26 
Synonyms 
 
Dibasic magnesium stearate; magnesium distearate; magnesia 
stearas; magnesium octadecanoate; octadecanoic acid, 
magnesiumsalt; stearic acid, magnesium salt 
Chemical Name Octadecanoic acid magnesium salt 
Molecular Weight 591.24 
Density (true)  1.092 g/cm3 
Loss on drying Not more than 6% 
Functional Category Tablet and capsule lubricant 
Solubility  Practically insoluble in ethanol, ethanol (95%), ether and 
water; slightly soluble in warm benzene and warm ethanol 
(95%). 
Stability and Storage 
Conditions 
Magnesium stearate is stable and should be stored in a well-
closed container in a cool, dry place. 
Incompatibilities Incompatible with strong acids, alkalis, and iron salts. Avoid 
mixing with strong oxidizing materials. Magnesium stearate 
cannot be used in products containing aspirin, some vitamins, 
and most alkaloidal salts. 
Application Magnesium stearate is widely used in cosmetics, foods, and 
pharmaceutical formulations. It is primarily used as a 
lubricant in capsule and tablet manufacture at concentrations 
between 0.25% and 5.0% w/w. It is also used in barrier 
creams. 
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Asparteme27, 28 
 
Synonyms 
 
3-Amino-N-(a-carboxyphenethyl)succinamic acid N-
methylester;  
3-aminoN(amethoxycarbonylphenethyl)succinamic acid; 
APM; aspartyl phenylamine methyl ester; Canderel; 
E951; Equal; methyl N-a-L-aspartyl-L-phenylalaninate; 
Nutra Sweet; Pal Sweet; Pal Sweet Diet; 
Chemical Name N-a-L-Aspartyl-L-phenylalanine 1-methyl ester 
Molecular Weight 294.31 
Density (true)  1.347 g/cm3 
Loss on drying <4.5% 
Functional Category Sweetening agent. 
Solubility  slightly soluble in ethanol (95%); sparingly soluble 
in water. At 208C the solubility is 1% w/v at the 
isoelectric point (pH 5.2). Solubility increases at higher 
temperature and at more acidic pH, e.g., at pH 2 and 
208C solubility is 10% w/v. 
Stability and Storage 
Conditions 
Aspartame degradation occurs during prolonged heat 
treatment; The bulk material should be stored in a well-
closed container, in a cool, dry place. 
Incompatibilities Differential scanning calorimetry experiments with some 
directly compressible tablet excipients suggests that 
aspartame is incompatible with dibasic calcium 
phosphate and magnesium stearate. Reactions between 
aspartame and sugar alcohols are also known. 
Application  Used as an intense sweetening agent in beverage 
products, food products, and table top sweeteners, and in 
pharmaceutical preparations including tablets, powder 
mixes, and vitamin preparations. It enhances flavor 
systems and can be used to mask some unpleasant taste 
characteristics; the approximate sweetening power is 
180–200 times that of sucrose.  
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6 METHODOLOGY 
6.1 Pre formulation studies 
6.1.1 A.P.I characterization by X-ray diffraction method29, 10 
6.1.1.1. Preparation of the sample 
47 mg of EMRB042 are suspended in 35 ml of TBME (tetra-methyl-butyl-ether) and 
heated up to 350C then 0.2 ml of methanol is added at 600C to increase the solubility. 
The clear solution is then filtered through 0.22µm Millipore filtration unit. The 
filtered solution is then cooled to room temperature till clear solution seeded with 
2mg of the ENRB042 form I. The obtained solution is further cooled to 50C and 
stored for 24 hours. The sample obtained was prepared in the disc shaped circular 
holder of 0.5 mm depth and 10mm width. 
6.1.1.2 Evaluation parameters 
X-ray powder diffraction measurement was performed on Philips 1710 powder X-ray 
diffractometer using cu Kα1 =1.54060 Å. The x-ray source is operated at 45kV and 
45mV spectra recorded at step size of 0.020 with continuing 2.4 seconds per step. 
6.1.2 Organoleptic properties of the A.P.I. 
Color: A small quantity of EMRB042 powder was taken in butter paper and viewed 
in well-illuminated place. 
Taste and odor: Very less quantity of EMRB042 was used to get taste with the help 
of tongue as well as smelled to get the odor. 
6.2 Physicochemical parameters of the A.P.I. 
6.2.1 Bulk density of the A.P.I 
A known quantity of powder was poured into the measuring cylinder carefully level 
the powder without compacting, if necessary and read the unsettled apparent volume, 
Vo, to the nearest graduated unit. Calculate the bulk density, in gm per ml, by the 
formula 
Bulk density = Bulk Mass/ Bulk Volume 
6.2.2 Taped density of the A.P.I 
After observing the initial volume, the cylinder is mechanically tapped and volume 
readings are taken until little further volume changes observed. Cylinder dropping 
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distance: 14± 2 mm at a normal rate of 300 drops / minute. Unless otherwise 
specified, tap the cylinder 500 times initially and measure the tapped volume, VA. 
Repeat the tapping an additional 750 times and measure the tapped volume, VB. If the 
difference between the two volumes is less than 2%, then it is the final tapped volume 
that is Vf. Repeat the same for 1250 taps, as needed, if the difference between 
succeeding measurements is less than 2%. Calculate the tapped density, in gm per ml, 
by the formula 
Tapped Density = 
Vf
m
 
6.2.3 Compressibility index of the A.P.I 
The compressibility Index and Hausner’s Ratio are measures of the propensity of a 
powder to be compressed. As such, they are measures of the relative importance of 
inter particulate interactions. In a free flowing powder, such interactions are generally 
less and tapped densities will be closer in value. For poorer flowing materials, there 
are frequently greater inter particle interactions, and a greater difference between bulk 
and tapped densities will be observed. These differences are reflected in the 
compressibility Index and the Hausner’s Ratio Calculated by the formula 
Compressibility index: = 
0
0 )(100
V
VfV −
 
Hausner’s Ratio: =
Vf
V0
 
6.2.4 Particle size analysis of A.P.I Malvern Mastersizer 2000 
Method: Dry method 
Procedure: Carefully assemble the flow cell and the lens into the main unit of the 
instrument. Connect small volume of dispersion cell to the main unit. Align the 
instrument after feeding the required parameters. Apply the pressure of 2 bar and feed 
rate of 50 % for proper cleaning of lenses. Measure the background. Add 1.0 gm of 
sample to the dry accessor and measure the sample by applying air pressure of 2 bar, 
feed rate of 50%. During the measurement laser obscuration should be between 2 to 6 
%. Analyze the sample and report. 
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6.3 Compatibility Study by D.S.C technology and HPLC technology 
Table no. 6.1 Drug-Excipients Compatibility Study 
Sample name 
Storage 
40°C/75% RH 1 M 
open 
40°C/75% RH 
1 M closed 
55°C 
1 M open 
EMRB042 Alone  Alone  Alone 
EMRB042 + Mannitol 
(1:1) (1:1) (1:1)
EMRB042 + Colloidal silicon 
dioxide 
(1:1)  (1:1)  (1:1) 
EMRB042 + Crospovidone (1:1) (1:1) (1:1)
EMRB042 + Croscarmellose 
sodium 
(1:1)  (1:1)  (1:1) 
EMRB042 + Aspartame (1:1) (1:1) (1:1)
EMRB042 + Peppermint flavor (1:1) (1:1) (1:1)
EMRB042 + Sodium stearyl 
Fumarate 
(1:1)  (1:1)  (1:1) 
EMRB042 + Pharmaburst (1:1) (1:1) (1:1)
EMRB042 + Ludiflash (1:1)  (1:1)  (1:1) 
EMRB042 + Prosolve ODT (1:1)  (1:1)  (1:1) 
EMRB042 + Prosolve ODT (1:1)  (1:1)  (1:1) 
 
EMRB042 was mixed with 1:1 proportion with all excipients to be used in our 
formulation and kept at 40°C/75% RH (close), 55°C (close), 55°C (open) for one 
month. The thermo grams & chromatograms obtained after month by D.S.C 
technology & HPLC technology studied to confirm the compatibility with the 
excipients 
6.3.1 H.P.L.C technology30 
The chromatographic column used was an Agilent ZorbaxSB-CN 250mm×4.6mm 
column with 5m particles. Mobile phase consists of a mixture of 10ml potassium di 
Hydrogen ortho phosphate, pH adjusted to 3.4 using diluted Orthophosphoric acid 
(solvent A), acetonitrile (solvent B) and Methanol (solvent C) the column temperature 
was maintained at 25oC and the wavelength was monitored at a wavelength of 225 
nm. The injection volume was 10µl for related substances determination and 5µl for 
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assay determination. Solvent A was used as diluent during the standard and test 
Samples preparation. 
6.3.1.1 Preparation of standard solutions 
A working solution of 500g/ml was prepared for related substances determination and 
assay determination analysis. A stock solution of Impurity (mixture of Imp-1, Imp-2 
and Imp-3) at 500g/ml was also prepared in diluents. 
 
6.3.2 D.S.C technology31 
The D.S.C study was performed on (pure A.P.I) and (A.P.I + excipients). 2 mg of the 
sample was kept in heat sensitive sealed aluminum pans sample mixture was 
constantly heated at a rate of 10oC/ min. in the range of 50oC to 220oC for 20 min. 
The nitrogen flow is controlled at the rate 20ml/min. Pressure of nitrogen was 
maintained constant at 2 τ (torr). The themogram obtained is evaluated on basis of the 
melting point of the A.P.I. 
 
6.4 Physicochemical parameters of powder blend. 
6.4.1 Particle size analysis of powder blend by Sieving method 
Procedure: This test was performed with the help of sieves of different size. They 
were fitted in the platform of sieve shaker in such a way that the coarse sieve was 
placed on top corresponding to the finer sieves. Placed 50 gm sample on the top and 
run the machine for 5 min. and took the weight of the retention on the sieve(s).Finally 
calculated the % of retention on each sieve by the following equation. 
100
50
retention ofquantity   retained % X=  
6.4.2 Flow properties of powder blend 
Procedure: A funnel was kept vertically in a stand at a specified height above a paper 
placed on a horizontal surface.  The funnel bottom is closed and 10 gm of sample 
powder is filled in funnel.  Then funnel was opened to release the powder on the 
paper to form a smooth conical heap, is found by measuring in different direction.  
The height of the heap was measured by using scale.  The values of angle of repose 
are calculated by using the following formula 
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tan θ = h/r 
θ = tan -1 h/r 
Where, h- height of the heap, 
r- Radius of the heap 
Angle of repose (Ø) Flowability
< 20 Excellent 
20-30 Good 
30-34 Acceptable 
> 40 Very poor 
 
For most pharmaceutical powders, the angle of repose values range from 25 to 45, 
with lower values indicating better flow characteristics. Values of angle of repose ≤ 
30 usually indicate a free flowing material and angle ≥40 suggest a poorly flowing 
material. 
6.4.3 Bulk density of powder blend 
Procedure: A known quantity of powder was poured into the measuring cylinder 
carefully level the powder without compacting, if necessary and read the unsettled 
apparent volume, Vo, to the nearest graduated unit. Calculate the bulk density, in gm 
per ml, by the formula 
Bulk density = Bulk Mass/ Bulk Volume 
6.4.4 Tapped density of powder blend 
Procedure: After observing the initial volume, the cylinder is mechanically tapped 
and volume readings are taken until little further volume changes observed. Cylinder 
dropping distance: 14± 2 mm at a normal rate of 300 drops / minute. Unless otherwise 
specified, tap the cylinder 500 times initially and measure the tapped volume, VA. 
Repeat the tapping an additional 750 times and measure the tapped volume, VB. If the 
difference between the two volumes is less than 2%, VB is the final tapped volume, 
VF. Repeat the same for 1250 taps, as needed, unit the difference between succeeding 
measurements is less than 2%. Calculate the tapped density, in gm per ml, by the 
formula. 
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Tapped Density = 
Vf
m
 
6.4.5 Measurement of Powder Compressibility 
The compressibility Index and Hausner’s Ratio are measures of the propensity of a 
powder to be compressed. As such, they are measures of the relative importance of 
inter particulate interactions. In a free flowing powder, such interactions are generally 
less and tapped densities will be closer in value. For poorer flowing materials, there 
are frequently greater inter particle interactions, and a greater difference between bulk 
and tapped densities will be observed. These differences are reflected in the 
compressibility Index and the Hausner’s Ratio Calculated by the formula 
Compressibility index: = 
0
0 )(100
V
VfV −
 
Hausner Ratio: = 
Vf
V0  
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6.5 Process Flow Chart of Direct compression 
Fig no.6.1 Process Flow Chart of Direct compression:- 
Step-1                                                                                                     step-2 
 
 
 
 
 
                                                            Step-3 
 
 
                                                             Step-4 
 
 
 
                                                              Step-5 
 
 
 
 
 
Sifting EMRB042 
and half quantity 
of mannitol co-
sifted through #40 
sieve (ASTM)  
Aspartame and 
polyplasdone ultra 
co sifted through 
#30 sieve. + 
Aerosil and 
peppermint  co 
sifted through #30 
sieve  
 Blending of step 1 and 2 materials in 
double cone blender for 10 min at 24 
Blending of Step 3, Sodium Stearyl Fumarate and mg. stearate 
(sifted through sieve # 60)in double cone blender for 5 min at 24 
rpm 
Step 4 blend was compressed into tablets on 16 
STN Compression Machine 
                                  Packing 
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Table no.6.2 Formulation of Trial batches F1-F6 
 
 
 
 
Sr. 
No. 
 
Ingredients 
Weight per Tablet (mg/tab) 
F1 F2 F3 F4 F5 F6 
1 EMRB042 14.53 14.53 14.53 14.53 14.53 14.53 
2 MANNITOL 73.00 73.0 -- -- -- 94.90 
3 PROSOLVE HD -- -- -- -- -- -- 
4 M.C.C. 41.87 43.87 -- -- -- 20 
5 CROSPOVIDONE 6.0 6.0 1.0 1.0 1.0 4.50 
6 CROSPOVIDONE (Extra granular) -- -- -- -- -- 4.50 
7 CROSCARMELLOSE SODIUM 6.0 6.0 -- -- -- 2.0 
8 AEROSIL 1 1 -- -- -- 0.50 
9 AEROSIL (Extra granular)      0.50 
10 LUDIFLASH -- -- 119.72 119.72 119.72 115.8 
11 CALCIUM SILICATE -- --- --- --- --- --- 
12 IPA: WATER (ML) -- --- --- --- --- Q.S 
13 ASPARTAME 1.60 1.60 11.25 11.25 11.25 1.60 
14 PEPPERMINT FLAVOR 0.0 0.0 2.0 2.0 2.0 0.50 
15 TALC -- -- -- -- -- -- 
16 SODIUM STEARYL FUMARATE 2.0 3.0 --- --- --- 3.0 
17 MAGNESIUM STEARATE 2.0 3.0 1.50 1.50 1.50 -- 
Total (mg) 150 150 150 150 150 150 
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Table no.6.3 Formulation of Trial batches F7-F13 
Sr. 
No. Ingredients 
Weight per Tablet (mg/tab) 
F7 F8 F9 F10 F11 F12 F13 
1 EMRB042 14.53 14.53 14.53 14.86 14.86 14.86 14.86 
2 MANNITOL 95.90 103.22 104.22 103.22 100.22 62.64 91.29 
3 PROSOLVE HD -- -- -- -- -- 30 -- 
4 M.C.C. 20 -- -- -- -- -- -- 
5 CROSPOVIDONE 4.50 15 26.60 26.60 26.60 -- -- 
6 CROSPOVIDONE (Extra granular) 4.50 -- -- -- -- -- -- 
7 CROSCARMELLOSE SODIUM 2 -- -- -- -- -- -- 
8 AEROSIL 0.50 0.15 0.15 0.15 0.15 1 0.75 
9 AEROSIL (Extra granular) 0.50 -- -- -- -- -- -- 
10 LUDIFLASH -- 115.82 -- -- -- -- -- 
11 CALCIUM SILICATE -- -- -- -- -- 7.50 7.50 
12 IPA: WATER (ML) q.s -- -- -- -- -- -- 
13 ASPARTAME 1.60 1 1 1 1 2 2 
14 PEPPERMINT FLAVOR -- 0.50 0.50 0.50 0.50 0.50 0.50 
15 TALC -- -- -- -- 3.0 -- -- 
16 SODIUM STEARYL FUMARATE 2.50 3.0 3.0 4.0 4.0 6.0 6.5 
17 MAGNESIUM STEARATE 2.50 -- -- -- -- -- -- 
18 POLY PLASDONE ULTRA -- -- -- -- -- 25.5 26.6 
Total (mg) 150 150 150 150 150 150 150 
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6.6 Evaluation 
6.6.1 Weight variation 
Twenty tablets were randomly selected and weighed to determine the average weight 
 
Limit USP
10% 130mg or less
7.5% 130mg to 324mg
5% More than 324mg
 
⎥⎦
⎤⎢⎣
⎡ −=
W
WW
F 0100  
F = Friability, W = Final weight, WO = Initial weight 
 
6.6.4 Hardness Test 
 The hardness of tablet was carried out by using “Pharmg hardness tester” hardness tester. 
6.6.5 Invitro Disintegration time  
Keep six tablets in Disintegration apparatus. Note the time required for the all six tablets to 
disintegrate completely without leaving any residue on the mesh of apparatus. Mesh size kept 
2mm (#10), stroke Cycles should be with rate of 28 to 32 cycles/min and 50 to 60 mm 
distance from bottom & top, control water temp 370C ± 20C. If 1 or 2 tablets fail, repeat for 
12 tablets. 
Limit for Orodispersible tablet  
Within 1 min 
6.6.6 Calculation for content uniformity 
USP: - Active less than 25mg or 25%. 
10 tablets limit NMT 1 tablet deviate 85 to 115% & none outside 75 to 125% of the Avg 
value/IP/BP/USP (Relative Standard Deviation less than or equal to 6%), 
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If 2 or 3 individual values are outside the limits 85 to 115% of the Avg value, & none outside 
75 to 125% repeat for 20 tablets. Complies when 30 tablets NMT 3 of the individual values 
are outside the limit 85 to 115% of the Avg value, and none outside 75 to 125%. 
 
6.6.7 Dissolution Study 
Medium     : 500 ml Phosphate buffer pH 6 
Apparatus  : Type II (paddle) 
Speed         : 50 rpm 
Time         : 5, 10, 15 min. 
Temperature                : 370C ± 0.5 0C 
λ max                : 225nm 
Perform the test on eight tablets place one tablet in each dissolution vessel containing 900 ml 
of water, at 370C ± 0.50C. At specified time withdrawn required amount of sample and take 
absorbance and calculate percentage release. 
6.6.8 Calculation of similarity and dissimilarity factors 
The similarity factor (f2) is a logarithmic transformation of the sum squared error of 
differences between the test Tt and reference products Rt over all time points. It represents 
closeness of two comparative formulations. Generally similarity factor in the range of 50 to 
100 is acceptable according to US FDA. Among several methods investigated for dissolution 
profile comparison, f2 is the simplest. Moore and Flanner proposed a model independent 
mathematical approach to compare the dissolution profile using two factors, f1 and f2.Where 
Rt and Tt are the cumulative percentage dissolved at each of the selected n time points of the 
reference and test product respectively. The factor f1 is proportional to the average difference 
between the two profiles, where as factor f2 is inversely proportional to the average squared 
difference between the two profiles, with emphasis on the larger difference among all the 
time points. The factor f2 measures the closeness between the two profiles. Because of the 
nature of measurement, f1 was described as difference factor, and f2 as similarity factor. In 
dissolution profile comparisons, especially to assure similarity in product performance, 
regulatory interest is in knowing how similar the two curves are, and to have a measure 
which is more sensitive to large differences at any particular time point. For this reason, the 
f2 comparison has been the focus in Agency guidance 
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Calculation formulas 
 
1) Dissimilarity factor 
f1= {[Σ t=1n |Rt-Tt|] / [Σ t=1n Rt]} ×100 
 
2) Similarity factor 
f2= 50×log {[1+ (1/n) Σ t=1n (Rt-Tt) 2] -0.5 ×100} 
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                            7 RESULTS AND DISCUSSION 
7.1 Characterizations by X-ray diffraction method 
Fig no-7.1 A.P.I characterization by X-ray diffraction method 
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Table no.7.1 X.R.D Analysis of A.P.I 
 
 
 
 
 
 
 
 
 
 
 
 
X-ray diffraction technique employed for the analysis of the A.P.I. Readings obtained are 
compared with the patented A.P.I to confirm the identification and confirmation of the 
compound type. It was found to be type A compound. The results obtained were similar to that 
of the patented A.P.I. So A.P.I identified and confirmed. 
 
 
 
 
 
EMRB042 
Angle °2θ  d‐ spacing (A°)  Qualitative RI 
18.6  4.76  100 
20.8  4.26  71 
22.0  4.03  70 
24.8  3.58  52 
16.8  5.26  46 
17.7  5.01  31 
26.0  3.41  27 
23.1  3.84  25 
22.5  3.94  24 
23.7  3.75  22 
19.1  4.64  21 
18.2  4.87  21 
15.7  5.65  19 
20.1  4.42  19 
23.9  3.70  18 
16.3  5.43  16 
28.7  3.10  16 
11.4  7.76  15 
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7.2 Physicochemical parameters of the A.P.I. 
7.2.1 Bulk density of the A.P.I 
The bulk density of the A.P.I was within the range of   0.425gm/ml to 0.477gm/ml. 
7.2.2 Taped density of the A.P.I 
The taped density of the A.P.I was within the range of 0.502 gm/ml to 0.565gm/ml. 
7.2.3 Compressibility index of the A.P.I 
The compressibility index was in the range of 14.28 to 16.13. 
7.2.4 Hausner’s ratio of the A.P.I 
 The Hausner’s ratio was in the range of1.16 to1.24 So as the reading indicates the A.P.I was 
having very poor flow rate  
7.2.5 Particle size of the A.P.I by Malvern Mastersizer 2000 
Fig no.7.2 Particle size analysis of A.P.I by Malvern Mastersizer 2000 
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Table no. 7.2 Particle size analysis of A.P.I by Malvern Mastersizer 2000 
Size(µm)  Vol under %  Size(µm) Vol under % Size(µm) Vol under % 
1.00  9.83  40.00 100.00 750.00 100.00 
1.445  16.10  50.00 100.00 800.00 100.00 
2.oo  26.87  60.00 100.00 900.00 100.00 
2.512  38.12  70.00 100.00 1000.0 100.00 
3.832  63.68  100.00 100.00 1500.0 100.00 
4.366  72.73  150.00 100.00 2000.0 100.00 
5.00  79.94  200.00 100.00 2500.00 100.00 
6.607  92.22  250.00 100.00 3000.00 100.00 
7.586  96.19  300.00 100.00 3500.00 100.00 
8.710  98.78  350.00 100.00 4000.00 100.00 
10.00  100.00  400.00 100.00 4500.00 100.00 
13.183  100.00  450.00 100.00 5000.00 100.00 
14.00  100.00  500.00 100.00    
15.00  100.00  550.00 100.00    
20.00  100.00  600.00 100.00    
25.00  100.00  650.00 100.00    
30.00  100.00  700.00 100.00    
 
D (0.5) value with the A.P.I was found to be 3.063, so A.P.I was found to be of desired particle 
size.  
7.3 Compatibility Study by D.S.C technology and HPLC technology 
7.3.1 H.P.L.C technology 
 
Table no 7.3 A.P.I-Excipients compatibility studies by HPLC technology 
Sample name Impurity 
 
Initial 
40°C/75% RH 
 1 M open 
40°C/75% 
RH  
1M closed 
55°C 1 M 
open 
 
EMRB042 
Benzoate 
Dimer 
impurity 
0.039 0.065 0.056 0.039 
Unknown 0.034 0.032 0.035 0.033 
Total 0.214 0.254 0.275 0.234 
EMRB042 
benzoate + 
Dimer 
impurity 
0.040 0.038 0.035 0.035 
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Mannitol Unknown 0.036 0.035 0.037 0.036 
Total 0.236 0.236 0.249 0.232 
EMRB042 + 
Colloidal silicon 
dioxide 
Dimer 
impurity 
0.023 0.000 0.025 0.000 
Unknown 0.122 0.033 0.125 0.127 
Total 0.360 0.190 0.401 0.351 
EMRB042 + 
Crospovidone 
Dimer 
impurity 
0.044 0.052 0.029 0.028 
Unknown 0.129 0.388 0.631 0.677 
Total 0.349 0.676 0.859 0.880 
EMRB042 + 
Croscarmellose 
sodium 
Dimer 
impurity 
0.000 0.000 0.000 0.000 
Unknown 0.030 0.029 0.035 0.036 
Total 0.162 0.178 0.195 0.166 
EMRB042 + 
Aspartame 
Dimmer 
impurity 
0.032 0.035 0.034 0.030 
Unknown 0.034 0.035 0.036 0.036 
Total 0.199 0.236 0.258 0.227 
EMRB042 + 
Peppermint 
flavor 
Dimer 
impurity 
0.032 0.030 0.029 0.027 
 Unknown 0.032 0.036 0.043 0.048 
Total 0.232 0.242 0.264 0.261 
EMRB042 + 
Sodium stearyl 
Fumarate 
Dimer 
impurity 
0.016 0.018 0.015 0.019 
Single 
unknown 
0.032 0.032 0.035 0.029 
Total 0.211 0.214 0.238 0.208 
EMRB042 + Dimer 0.034 0.033 0.028 0.035 
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7.3.2   The thermo gram obtained by the D.S.C technology with pure A.P.I and mannitol: 
 
 
Fig no.7.4 The thermo gram obtained by the D.S.C technology with pure A.P.I and mannitol 
 
No significant change is observed in melting point. 
 
7.3.4 The thermo gram obtained by the D.S.C technology with pure A.P.I and polyplasdone XL:- 
 
 
Fig no.7.5 Thermo gram obtained by D.S.C technology with pure A.P.I and polyplasdone XL 
 
No significant change in the melting point is observed 
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7.3.4 The thermo gram obtained by the D.S.C technology with pure A.P.I and peppermint flavor 
 
Fig no.7.6 Thermo gram obtained by D.S.C technology with pure A.P.I and peppermint flavor 
  
 No significant change in the melting point is observed 
 
7.3.5 The thermo gram obtained by the D.S.C technology with pure A.P.I and Aspartame 
 
Fig no 7.7 The thermo gram obtained by the D.S.C technology with pure A.P.I and Aspartame 
 
  No significant change in the melting point .All excipients were found to be compatible with the 
A.P.I  
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 7.4 Evaluation of powder blend 
The prepared granules were evaluated for the blend property like Bulk density, Tapped density, 
Carr’s index, Hauser ratio and Angle of repose. Results obtained were as shown in Table 8.3 
below- (n = 3) 
Table no. 7.4 Evaluation of powder blend 
Formul
ations 
Bulk 
density(g/ml) 
±SD 
Tapped 
density (g/ml) 
±SD  
Carr’s index 
(%)±SD  
Hausner ratio 
(%)±SD 
F1 0.444 0.526 15.55 1.18 
F2 0.476 0.571 16.66 1.20 
F3 0.476 0.565 14.28 1.16 
F4 0.425 0.502 14.89 1.17 
F5 0.430 0.507 15.04 1.18 
F6 0.462 0.544 16.13 1.26 
F7 0.456 0.536 15.89 1.24 
F8 0.439 0.516 15.29 1.19 
F9 0.477 0.560 16.59 1.29 
F10 0.434 0.509 15.07 1.17 
F11 0.445 0.521 15.42 1.19 
 
The above result showed that, the Carr’s index in the range of 10-20% which is considered as 
excellent to good flowing property. Similarly, the bulk density and tapped density value was 
found to be less than one hence showed excellent to good flow property. All these results 
indicate that, the powder blend possess satisfactory flow and compressibility properties for 
directly compressible formulation.  
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7.5 Physical evaluation of tablets 
All the tablet preparations were evaluated for various physical parameters and assay before 
proceeding further. Following table includes the values (mean ± SD) of weight variation, 
hardness, diameter and thickness of 11 tablet batches prepared using different combinations of 
functional excipients.  
Table no.7.5 Evaluation of tablets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The percentage friability, as depicted in table was in the range 0.06 to 0.2. Tablet weight in all 
the eight batches varied in range of 149.0 to 151.0. Thickness was in the range of 3.24 mm to 
3.64 mm and tablet hardness between 2.01 to 5.4. Thus, all the physical parameters of the 
compressed tablets were within control. 
 
 
Formulation Hardness (Kp) Weight Uniformity(mean) (mg)
Friability 
(%) 
Thickness 
(mm) 
F1 3.01 – 4.23  149 
0.067 
 
3.31 - 3.32 
 
F2 3.01 – 4.23  149 
0.067 
 
3.31 - 3.32 
 
F3 2.74-3.50  150.8 
0.301 
 
3.24-3.26 
 
F4 2.35 – 3.30  149.7 
0.215 
 
3.48 – 3.53 
 
F5 2.35 – 3.30  149.7 
0.215 
 
3.48 – 3.53 
 
F6 3.25 – 4.07  149.8 
0.121 
 
3.52 – 3.54 
 
F7 3.80– 5.28  151.2 
0.106 
 
3.56 – 3.59 
 
F8 2.01-2.92  149.5 
0.045 
 
3.26-3.33 
 
F9 3.88 -4.43  150.1 
0.076 
 
3.50 - 3.53 
 
F10 4.7-5.6  151.1 -- 
3.64-3.66 
 
F11 5.4-8.01  150.3 -- 
3.58-3.66 
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7.5.1 In vitro Disintegration time 
The disintegration study was carried on all formulations except formulation no.1 and formulation 
no.6 as sticking was observed, the disintegration study of remaining formulations are as follows.  
 
Table no 7.6 Values of Disintegration time orodispersible 
 
 
 
 
 
 
 
 
 
It was observed that tablets of all the eleven formulations had a disintegration time of less than 
30 sec. and hence they passed the test for disintegration time. It was seen that formulation 
batches 4, 5, 10, 11, had a disintegration time less than 20 sec. i.e. the disintegration time was 
found to decrease. However, at higher concentrations of Croscarmellose sodium and calcium 
silicate i.e about 4 to 5 % of either of them drastically decreases the disintegration time.  
7.5.2 Uniformity of Content 
The drug content for tablets of all formulation was found to be in the range of. -101.3±1.33 thus 
all formulation batches of EMRB042 passes the content uniformity test. 
 
 
 
 
 
 
 
Formulation Disintegration Time(Sec) 
F2 20 sec 
F3 20 sec 
F4 19 Sec 
F5 14 Sec 
F7 14 Sec 
F8 22 sec 
F9 24 sec 
F10 24 se 
F11 24 sec 
F12 16 sec 
F13 12 sec 
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7.5.3 In vitro Dissolution Studies   
The dissolution study was carried on all formulations except formulation no. 1 and formulation 
no.6 as sticking was observed, the dissolution study of remaining formulations are as follows.  
FORMULATION 2 
Percentage release of EMRB042 in water of optimum formulations prepared by employing direct 
compression technique 
 
 
 
 
 
 
 
 
 
Fig no. 7.8 Percentage release of F2 
Table no.7.7 Dissolution profile of F2 
 
The % release after infinity period of 30 min with 200rpm was not complete with formulation 
no. 2.As the release was not complete, it was decided to use ludiflash for direct compression 
method. 
 
 
Time points 
 
% DRUG RELEASE 
5 min 10 min 15 min Infinity F2 
Reference 69.4 95.6 99.2 100.4  
Test Product 55.6 71.9 75.2 80.5 39.0 
0.0
20.0
40.0
60.0
80.0
100.0
0.0 5 min 10 min 15 min Infinity
Innovator Tabs, B.no.: 0442250 (n=6, 50rpm)
Test tabs, B.No.: 255/006 (n=3, 50 rpm)        
Dissolution Data Comparison
Time in min
%
 D
ru
g 
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le
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e
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FORMULATION 3 
Percentage release of EMRB042 in water of optimum formulations prepared by employing direct 
compression technique with ludiflash 
 
Fig no.7.9 Percentage release of F 3 
Table no.7.78 Dissolution profile of F 3 
 
After period of 15 min. with 50rpm % release was on higher side compared to formulation no. 2. 
It was decided to further investigate the effect of particle size reduction of EMRB042 on 
dissolution profile. So two batches were designed with milled EMRB042 and micronized 
EMRB042  
 
 
 
 
0.0
20.0
40.0
60.0
80.0
100.0
0.0 2 min 4 min 6 min 8 min 10 min 12 min 15 min
Innovator Tabs, B.no.: 0442250 (n=6, 50rpm)
B.No.: 255/018(n=6, 50 rpm)        
Dissolution Data Comparison
Time in min
%
 D
ru
g 
re
le
as
e
Time points % DRUG RELEASE 
2Min 4Min 6Min 8Min 10Min 12Min 15Min F2 
Innovator 69.5 89.7 93.1 97.5 97.8 97.5 98.7  
Formulation 
No.3 
75.2 86.5 90.4 91.0 91.8 91.4 91.9 64.0 
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Formulation 4 & 5 
Percentage release of EMRB042 in water of formulations prepared by employing direct 
compression technique 
 
Fig no 7.10 Percentage release of F 4 & 5 
Table no.7.9 Dissolution profile of F4 & F5 
Time points % DRUG RELEASE
 2 min 4min 6min 8min 10min 12min  15 min F2 
API milled 
F4 
5.2 25.5 60.9 78.9 87.0 89.9 94.1 52 
APImicronized-
F5 
7.1 32.0 63.7 80.3 87.1 89.7 90.4 47 
 
After 15 min the % release of drug observed was better in milled EMRB042 (200 mesh passed) 
than micronized EMRB042. As the release pattern was better in formulation containing milled 
EMRB042, so it was decided to use milled EMRB042, but % release was not complete so it was 
decided to use wet granulation technique. 
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FORMULATION 7 
Percentage release of EMRB042 in water of optimum formulations prepared by employing wet 
granulation technique 
 
Fig no.7.11 Percentage release of F 7 
Table no.7.10 Dissolution profile of F 7 
Time points 
% DRUG RELEASE 
2 min 4 min 6 min 8 min 10 min 12 min 15  min F2 
Reference 69.5 89.7 93.1 97.5 97.8 97.5 98.7 - 
Formulation 7 51.9 70.7 76.9 79.8 79.9 80.4 80.6 
39.0 
 
 
 After 15 min the % release observed was not complete. As the dissolution profile obtained with 
the approach of wet granulation was not 100 % after 15 min it was decided to stick with the 
approach of direct compression formulation with ludiflash and reduce the concentration of 
peppermint and to use sodium Stearyl Fumarate instead of mg. stearate. 
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FORMULATION 8 
Percentage release of EMRB042 in water of optimum formulations prepared by employing direct 
compression technique with reduced concentration of peppermint and use of sodium Stearyl 
Fumarate instead of mg. stearate  
 
Fig no.7.12 Percentage release of F 8 
Table no.7.11 Dissolution profile of F8 
Time points  % DRUG RELEASE 
2 min 4 min 6 min 8 min 10 min 12 min 15  min F2 
Innovator 69.5 89.7 93.1 97.5 97.8 97.5 98.7 - 
Formulation 8 65.5 89.7 98.1 99.0 99.5 98.8 100.1 79.0 
 
The % release after time period of 15 min observed was better than the innovator. The % release 
after time period of 15 min Observed was better than innovator so it was decided to kip sodium 
Stearyl Fumarate as the only lubricant in the formulation. The formulation was kept for the 
stability in 40°C temperature with 75% Relative humidity.  
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Table no.7.12 Test product (Ludiflash formula) - stability data of F8 
EMRB 042 ODT 
Pack Details: HDPE Bottle 
Sr. 
No.  
Test  Specifications  Initial 
Analysis  
55°C 
(Open) 
40°C/75%RH  
15Days 15 days 15 days 
1  Dissolution (%)   Time Points      
0.1N HCl ,500 ml, 
USP Type II 
50 rpm 
5 min  Na 11.3 26.7 12.5 
10 min  91.4 16.5 47.6 32.4 
15 min  89.8 27.9 70.6 50.5 
30 min  Na 54.9 84.3 Na 
2  Water Content (%)  To  establish 2.99 NP NP NP 
3  Assay (%)  90.0 – 110.0 97.89 97.02 97.83 97.36 
 Related Substances 
(%)  
Tentative limits     
Dimer  0.5% ND ND ND ND 
4   Unknown  0.2% 0.103 0.808 0.586 0.584 
Total Impurities  2.0% 0.180 0.964 0.700 0.687 
 
Though assay after 15 days was within the limits, the range of single unknown impurity observed 
was 0.687 which is not acceptable. Formulation was not stable over 15 days in stability 
conditions of 40°C Temperature and 75% relative humidity. It was decided to remove ludiflash 
from formulation as ludiflash contains crosspovidone which carries traces of organic solvents 
with it & may cause oxidation of the EMRB042.Resulting rise in unknown impurity. Mannitol 
was decided to be used as filler because of its high Solubility of 42gms/ml. 
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FORMULATION 9 
Percentage release of EMRB042 in water of optimum formulations prepared by employing direct 
compression technique with mannitol as filler   
 
 
 
 
 
 
 
 
Fig no.7.13 Percentage release of F 9 
                                               Table no:-7.13 Dissolution profile of F9 
Time points 
% DRUG RELEASE
2 min 4 min 6 min 8 min 10 min 12 min 15 min F2 
Innovator 69.5 89.7 93.1 97.5 97.8 97.5 98.7 - 
Formulation 9 55.5 85.7 94.6 96.7 97.1 96.8 97.8 64.0 
 
Dissolution profile obtained was better than the innovator with formulation with mannitol as 
filler. As the profile obtained was satisfactory it was decided to further investigate the role of 
mannitol with different grades. Mannitol SD 200 & Mannitol 300 DC were selected as a 
requirement of formulation for better solubility, Stability and release profile. 
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FORMULATION NO:-10 & 11 
Percentage release of EMRB042 in water of optimum formulations prepared by employing direct 
compression technique 
 
Fig no.7.14 Percentage release of F10 & F11 
Table no:-7.14 dissolution profile of F10 & F11 
 
Time points 
% DRUG RELEASE 
2 min 4 min 6 min 8 min 10 min 12 min 15  min F2 
Reference 69.5 89.7 93.1 97.5 97.8 97.5 98.7 - 
annitol 300DC F10 69.7 95.1 100.9 102.2 103.1 103.6 104.6 64 
Mannitol SD200     
F11 
62.3 92.4 96.7 99.2 100.7 101.6 101.9 71 
 
Dissolution profile obtained was better than the reference in both mannitol grade formulations 
specifically mannitol with grade 300DC has shown better results as compare to SD 200. As the 
results obtained with both mannitol grades are better than the reference, F10 kept for stability 
study in   40°C Temperature and 75% Relative humidity. 
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Table no:-7.15 Test product Stability data of F10 
EMRB 042 ODT 
Sr. No.  Test  Specifications  Initial 
Analysis 
55°C (Open) 40°C/75%RH  
15Days 15 days 15 
days 
1  Dissolution (%  Time Points      
Deaerated 
water ,900 ml, 
USP Type II 
50 rpm 
5 min  Na 78.8 76.9 39.4 
10 min  97.1 93.2 95.0 70.8 
15 min  97.8 94.9 97.0 83.7 
30 min  Na 96.2 96.4 90.3 
2  Water Content 
(%)  
To be established 3.86 3.57 3.49 3.77 
3  Assay (%)  90.0 – 110.0            97.18 97.18 97.60 97.53 
4  Related 
Substances (%)  
Tentative limits     
Dimer  0.2% ND ND ND ND 
 Unknown  0.2% 0.192  1.744 0.610  1.115  
Total 
Impurities  
2.0% 0.328 1.917 0.739 1.249 
 
Even though % release obtained with F10 was complete after 15 days, stability issue continued with 
the formulation. As the single unknown impurity observed was 1.249 which is not acceptable.As the 
stability issue continued even with the mannitol formulation it was decided to use  prosolve HD 
(silicified microcrystalline cellulose), polyplasdone ultra (cross povidone) &  hubersorb  250 
(Calcium  silicate)   
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FORMULATION NO -12 &13 
Percentage release of EMRB042 in water of optimum formulations prepared by employing direct 
compression technique  
 
Fig no. 7.15 Percentage release of F 12 & F13 
Table no .7.16 Dissolution profile of F12 & F13 
 
 
 
 
 
 
 
Percent release obtained with the prosolve HD (silicified microcrystalline cellulose), 
polyplasdone ultra (cross povidone) & hubersorb 250 (Calcium silicate), was complete as well as 
better than reference sample. Dissolution profile obtained from this formulation was fond to be 
satisfied so it was decided to keep it for stability in 400C temperature and 75% relative humidity.  
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Table no. 7.17 Test product stability data of F12 
EMRB 042 ODT 
Sr. 
No. 
Test Specifications Initial 
Analysis 
40°C/75%RH 
15 days 1month 2month 
1 Dissolution (% Time Points     
Deaerated 
water ,900 ml, 
USP Type II 
50 rpm 
5 min 101.2 Na na Na 
10 min 101.2 97.3 90.6 89.0 
15 min 100.5 97.3 97.3 98.4 
30 min 101.2 Na na Na 
2 Water 
Content (%) 
 4.46 4.26 NP 3.74 
3 Assay (%) 90.0 – 110.0 100.81 98.66 100.04 96.28 
4 Related 
Substances (%) 
Tentative limits 
N-oxide 0.2% 0.034 0.046 0.046 0.068 
Unknown 0.2% 0.049 0.044 0.044 0.050 
Total 
Impurities 
2.0% 0.139 0.133 0.150 0.162 
 
The total impurity at the end of two months was 0.162 with F12 which is acceptable limit. 
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Table no 7.18 Test product stability data of F13 
EMRB 042 ODT 
Sr. 
No. 
Test Specifications Initial 
Analysis 
40°C/75%RH 
15 days 1month 2month 
1 Dissolution (% Time Points     
Deaerated 
water ,900 ml, 
USP Type II 
50 rpm 
5 min 97.3 na na Na 
10 min 99.5 96.2 95 66 
15 min 99.6 96.3 95.4 92.1 
30 min 99.6 na na Na 
2 Water Content 
(%) 
 3.78 3.40 3.84 3.09 
3 Assay (%) 90.0 – 110.0 101.48 101.75 100.12 101.28 
4 Related 
Substances (%) 
Tentative limits 
N-oxide 0.2% 0.027 0.038 0.05 0.075 
Unknown 0.2% 0.052 0.048 0.048 0.053 
Total 
Impurities 
2.0% 0.141 0.129 0.164 0.179 
 
The total impurity at the end of two months with F13 was 0.179 which is in an acceptable limit. 
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8 SUMMARY 
EMRB042 is an anti-migraine drug used to control the acute migraine attacks with or without 
aura. It is well absorbed from the gastrointestinal tract. However, the faster release of the drug 
was expected for faster relief in the acute attacks of the migraine. So there is strong need to 
enhance the disintegration & dissolution rate of the formulation. The half life of the drug is 2to 3 
hrs. Therefore, it is suitable drug for design of fast dissolving tablets with a view to improve its 
oral bioavailability. 
In present study, an attempt was made to design ODTs of EMRB042 using super  disintegrant 
like croscarmellose sodium, Crospovidone, microcrystalline cellulose to decrease the 
disintegration time of tablets and also to increase drug bioavailability. 
Characterization of the A.P.I was done by XRD, which confirmed the A.P.I is crystal form I.  
Selections of excipients were done as per the requirement of the formulation. As aim was to 
formulate the ODT formulation, most simple technology of direct compression was followed. 
Basic categories of excipients like filler, super disintegrant, binder, sweetener, lubricant, glident 
ware identified and accordingly excipients were selected. As the A.P.I is sensitive to oxidation, 
excipients were selected containing low peroxide content to prevent the oxidation. Selected 
excipients we subjected to compatibility study.  
In compatibility study A.P.I was kept with all the excipients in 1:1 proportion to study the 
possible interaction. Drug and excipients were subjected to three different conditions of 
temperature and relative humidity, 400 C/75% RH open, 400C/75%RH closed, 550C closed for 
the period of 1 month and then samples were evaluated for the compatibility using HPLC 
technology and D.S.C technology. HPLC and DSC study suggested there is no interaction 
between the drug and excipients.  
Formulations were prepared by direct compression method and evaluated, for the parameters 
such as weight variation, content uniformity, friability, hardness, disintegration time, dissolution 
profile, assay, and stability.  
Formulation 1 showed sticking on both the punch surface so it was decided to increase the 
concentration of the magnesium stearate, sodium Stearyl Fumarate up to 2%.   
Formulation 2 with reduced concentration of the lubricant showed incomplete release of the 
A.P.I of 75% at the end of the 15min where as reference sample showed 100%. So it was 
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decided to use ludiflash as filler which is the combination of three excipients mannitol, 
crospovidone, and polyvinyl acetate. 
Formulation 3 with ludiflash as filler showed % release of 94%.  
To study the effect of particle size on dissolution profile of the drug milled A.P.I and micronized 
A.P.I used in formulation 5 & formulation 6 respectively both the formulations showed release 
of  94% and 90%  respectively after 15min. So it was decided to keep formulation 5 for stability. 
Evaluation of formulation 5 on the 15th day showed unknown impurity above the limit. 
Formulation 6 designed with the approach of wet granulation which showed sticking on both 
punches. 
Formulation 7 designed with wet granulation and increased concentration of 1.7 %  so no 
sticking was observed. The % release was 80% so it was decided to stick with direct 
compression method. 
Formulation 8 was designed with reduced concentration of peppermint flavor and sodium stearyl 
fumarate instead of magnesium stearate. Percentage release was 100 %. So formulation 8 was 
kept for stability but impurity level crossed acceptable limit over the period of 15 days. So it was 
decided to use mannitol as filler.  
Formulation 9 with mannitol showed release of 98.8% of release. So to study the effect of the 
mannitol particle size two grads of mannitol were selected. 
Formulation 10 with pearlitol 300DC and formulation 11 with pearlitol SD200 were designed 
both the formulations showed complete release but formulation 10 showed better release profile. 
So it was kept for stability. But impurity level crossed the acceptable limit within 15days.so it 
was decided to add prosolve HD, polyplasdone ultra & Calcium silicate. 
Formulation 12 designed with prosolve, polyplasdone ultra & Calcium silicate showed 100% 
release were as formuletion 13 with increased level of showed polyplasdone ultra showed 100% 
release. both of these formulations were found to be stable over the period of 2 months. So both 
the formulations ware selected as the final optimized formulations.  
 
 
